Nonviral circular single-stranded DNA systems and their applications
By using the LNP system of LSR and cssDNA, the sequence of interest is integrated into the cell genome, solving the problem of DNA gene delivery triggering an immune response in existing technologies, and realizing effective CAR-T cell therapy in T cells.
Patent Information
- Application Number
- CN202580020448.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2025-01-10
- Filing Date
- 2025-03-11
- Publication Date
- 2026-11-10
AI Technical Summary
Existing technologies lack non-viral methods for delivering DNA genes into cells without triggering unwanted immune responses, and require the integration of sequences of interest into the cell genome.
A lipid nanoparticle (LNP) system containing mRNA encoding large serine recombinase (LSR) and circular single-stranded DNA (cssDNA) was used to integrate sequences of interest into the cellular genome via LNP-mediated integration, avoiding the need to engineer cells to install attachment sites.
Successful integration and expression of the sequence of interest in cells was achieved, reducing immunogenicity, and showing significant CAR-T cell therapeutic potential, particularly in T cells.
Smart Images

Figure CN123076676A_ABST
Abstract
Description
Technical Field
[0001] This disclosure relates to compositions and systems for LNP-mediated delivery of circular single-stranded DNA (cssDNA) into cells, and methods for introducing, modifying, or editing nucleic acids using such systems.
[0002] sequence list
[0003] This application contains a sequence list that has been electronically submitted in XML format. The XML copy created on March 3, 2025, is named “01373-0003-00PCT.xml” and has a size of 1,082,703 bytes. Information from the electronic sequence list is incorporated herein by reference in its entirety. Background Technology
[0004] Nucleic acid-based drugs have become an increasingly important treatment modality for various medical indications, including in cancer immunotherapy and genetic diseases. However, there remains an unmet need for non-viral methods that use DNA for gene delivery without triggering unintended immune responses. Such non-viral methods would offer novel therapies for integrating genes into the cellular genome. The compositions, systems, and methods comprising recombinases described herein can be used in a variety of diagnostic and therapeutic settings, such as for the treatment of human diseases and conditions. Summary of the Invention
[0005] In some embodiments, this disclosure provides a genome editing system comprising: a) mRNA encoding a large serine recombinase (LSR); and b) circular single-stranded DNA (cssDNA) containing a donor attachment site (AttD) and a sequence of interest; wherein the genome editing system is capable of integrating the sequence of interest into a cellular genome. In some embodiments, this disclosure provides a composition comprising (a) mRNA encoding a large serine recombinase (LSR), (b) cssDNA containing a donor attachment site (AttD) and a sequence of interest, (c) lipid nanoparticles, and optionally (d) additional components, wherein the composition is capable of integrating the sequence of interest into a cellular genome.
[0006] In some embodiments described herein, additional components besides cssDNA and mRNA and lipid nanoparticles as described herein are optional and not required. Furthermore, in some embodiments, it is not necessary to engineer cells to incorporate attachment sites (also known as “landing pads”) for the integration of sequences of interest into them.
[0007] In some embodiments, the genome editing system comprises lipid nanoparticles (LNPs). In some embodiments, the ratio of CSSDNA to mRNA in the genome editing system is 3:1 to 1:3. In some embodiments, the ratio of CSSDNA to mRNA in the genome editing system is 2:1 to 1:2. In some embodiments, the ratio of mRNA to CSSDNA in the genome editing system is 1:1.
[0008] In some cases, the genome editing system also includes a lipid-based formulation comprising (a) and (b). In some embodiments, the genome editing system further includes a first lipid-based formulation comprising (a) and a second lipid-based formulation comprising (b).
[0009] In some respects, (b) the endotoxin level is less than 0.1 EU / µg, less than 0.05 EU / µg, 0.01 EU / µg or 0.005 EU / µg.
[0010] In some implementations, the sequence of interest in the genome editing system contains a gene or a portion of a gene. In some cases, the sequence of interest contains a therapeutic protein.
[0011] In some embodiments, the sequence of interest encodes a CAR. In some embodiments, the CSSDNA exhibits reduced immunogenicity in an organism compared to a composition or genome editing system containing dsDNA encoding the sequence of interest. For example, in some embodiments, reduced immunogenicity may be manifested by lower levels of inflammatory cytokines (such as IL-6, IFN-β, IFN-α, and / or MCP-1) and / or no significant change in body weight in subjects who have been administered the system compared to a system containing dsDNA encoding the sequence of interest.
[0012] In some embodiments, the genome editing system disclosed herein includes an mRNA encoding a LSR, wherein the LSR is a genome-targeting LSR. Therefore, in some embodiments, the LSR is not a landing pad LSR.
[0013] In some embodiments, the genome editing system comprises a lipid-based formulation. In some cases, the lipid-based formulation comprises cationic lipids, accessory lipids, cholesterol, and PEG lipids. In some cases, the lipid-based formulation also comprises a peptide. In some embodiments, the peptide comprises a targeting moiety. The targeting moiety may comprise, for example, an antibody or an antibody fragment.
[0014] In some implementations, the lipid-based formulation is lipid nanoparticles (LNPs). In some aspects, LNPs have a size of 50-100 nm.
[0015] In some embodiments, the genome editing system comprises a first lipid-based formulation containing mRNA encoding a large serine recombinase (LSR); and a second lipid-based formulation containing circular single-stranded DNA (cssDNA) containing a donor attachment site (AttD) and a sequence of interest. In some embodiments, the first and second lipid-based formulations are substantially identical in composition and size.
[0016] In some embodiments, the first lipid-based formulation comprises mRNA encoding a large serine recombinase (LSR), and the second lipid-based formulation comprises circular single-stranded DNA (cssDNA) containing a donor attachment site (AttD) and the sequence of interest. In some embodiments, the first lipid-based formulation and the second lipid-based formulation differ in composition and size.
[0017] In some embodiments, the AttD site comprises at least 26, 34, 36, 39, 48, or 52 nucleotides, wherein these nucleotides comprise a dinucleotide core and an even number of nucleotides directly adjacent to it on either side. In some embodiments, AttD comprises an AttP site. In some embodiments, the cellular genome is a human genome. In some embodiments, the cellular genome does not contain an attachment site.
[0018] This document also provides methods for generating engineered cells, including contacting the cells with any of the compositions disclosed herein or a genome editing system. In some embodiments, methods for introducing a sequence of interest into cells are provided, including contacting the cells with any of the compositions disclosed herein or a genome editing system. In some embodiments, engineered cells are provided, wherein the engineered cells contain an integrated sequence of interest from any of the compositions disclosed herein or a genome editing system. In some embodiments, methods for treating a disease in a subject are disclosed, including administering any of the compositions disclosed herein, a genome editing system, or engineered cells to the subject. In some embodiments, the disease is cancer.
[0019] In some embodiments, the cells used to express the sequence of interest in the genome editing system, method, or engineered cells disclosed herein are dividing cells. In some embodiments, the cells are non-dividing cells. In some embodiments, the cells are T cells. In some embodiments, the sequence of interest in the composition, genome editing system, or engineered cells comprises a CAR. In some embodiments, no cell engineering is required to incorporate any attachment sites (also referred to as “landing pads”) to which the sequence of interest is to be integrated.
[0020] A method for integrating a sequence of interest into a cell genome is also provided, the method comprising contacting a cell with the composition or genome editing system described herein, such that the sequence of interest is integrated into the cell genome. In some cases, the cell is a mammalian cell. In some cases, the cell is a human cell. In some embodiments, the cell is a T cell, a natural killer cell (NK cell), a non-human embryonic stem cell, an induced pluripotent stem cell (iPSC), a hematopoietic stem cell (HSC), a hepatocyte, a myocyte, a monocyte, a B cell, a neuron, an astrocyte, or a microglia. In some embodiments, the cell is a T cell. In some embodiments, the sequence of interest comprises a CAR. In some embodiments, the cell contact is in vivo. In some embodiments, the cell contact is ex vivo. In some embodiments, no Cas or guide RNA is used in the cell contact. In some embodiments, the method results in the generation of CAR-T cells. In some embodiments, no cell engineering is required to incorporate any attachment sites (also referred to as “landing pads”) into which the sequence of interest is to be integrated.
[0021] Therefore, some implementations described herein include, for example:
[0022] Implementation Scheme 1: A genome editing system, the genome editing system comprising:
[0023] a) mRNA encoding macroserine recombinase (LSR); and
[0024] b) Circular single-stranded DNA (cssDNA) containing a donor attachment site (AttD) and the sequence of interest;
[0025] The genome editing system described therein is capable of integrating the sequence of interest into the cell genome.
[0026] Implementation Scheme 2: The genome editing system as described in Implementation Scheme 1, wherein the genome editing system further comprises a lipid-based formulation containing (a) and (b).
[0027] Implementation Scheme 3: The genome editing system as described in Implementation Scheme 1, wherein the genome editing system further comprises a first lipid-based formulation comprising (a) and a second lipid-based formulation comprising (b).
[0028] Implementation Scheme 4: A genome editing system as described in Implementation Scheme 2 or 3, wherein the lipid-based formulation is LNP.
[0029] Implementation Scheme 5: A genome editing system as described in any one of Implementation Schemes 1 to 4, wherein the ratio of b) to a) in the genome editing system is 3:1 to 1:3, or wherein the ratio of b) to a) in the genome editing system is 2:1 to 1:2.
[0030] Implementation Scheme 6: A genome editing system as described in any one of Implementation Schemes 1 to 5, wherein the ratio of b) to a) in the genome editing system is 1:1.
[0031] Implementation Scheme 7: A genome editing system as described in any one of Implementation Schemes 1 to 6, wherein (b) has an endotoxin level of less than 0.1 EU / µg, less than 0.05 EU / µg, 0.01 EU / µg, or 0.005 EU / µg.
[0032] Implementation Scheme 8: A genome editing system as described in any one of Implementation Schemes 1 to 7, wherein the sequence of interest comprises a gene or a portion thereof.
[0033] Implementation Scheme 9: A genome editing system as described in any one of Implementation Schemes 1 to 8, wherein the sequence of interest comprises a therapeutic protein.
[0034] Implementation Scheme 10: A genome editing system as described in any one of Implementation Schemes 1 to 9, wherein the sequence of interest comprises a CAR.
[0035] Implementation Scheme 11: A genome editing system as described in any one of Implementation Schemes 1 to 10, wherein the LSR is a genome-targeting LSR.
[0036] Implementation Scheme 12: A genome editing system as described in any one of Implementation Schemes 1 to 11, wherein the LSR is not a landing pad LSR.
[0037] Implementation Scheme 13: A genome editing system as described in any one of Implementation Schemes 1 to 12, wherein the genome editing system comprises a lipid-based formulation, including a lipid-based formulation comprising cationic lipids, auxiliary lipids, cholesterol and PEG lipids.
[0038] Implementation Scheme 14: The genome editing system as described in Implementation Scheme 13, wherein the lipid-based formulation further comprises a peptide.
[0039] Implementation Scheme 15: A genome editing system as described in any one of Implementation Schemes 2 to 14, wherein the lipid-based formulation comprises LNPs with a size of 50-100 nm.
[0040] Implementation Scheme 16: A genome editing system as described in any one of Implementation Schemes 1 to 15, the genome editing system comprising a) a first lipid-based formulation and b) a second lipid-based formulation, wherein the first lipid-based formulation and the second lipid-based formulation are substantially identical in composition and size.
[0041] Implementation Scheme 17: A genome editing system as described in any one of Implementation Schemes 1 to 16, the genome editing system comprising a) a first lipid-based formulation and b) a second lipid-based formulation, wherein the first lipid-based formulation and the second lipid-based formulation are different in composition and size.
[0042] Implementation Scheme 18: A genome editing system as described in any one of Implementation Schemes 1 to 17, wherein the AttD site comprises at least 26, 34, 36, 39, 48, or 52 nucleotides, wherein the nucleotides comprise a dinucleotide core and an even number of nucleotides directly adjacent to either side of the dinucleotide core.
[0043] Implementation Scheme 19: A genome editing system as described in any one of Implementation Schemes 1 to 18, wherein the AttD site comprises the AttP site.
[0044] Implementation Scheme 20: A genome editing system as described in any one of Implementation Schemes 1 to 19, wherein the cell genome is a human genome.
[0045] Implementation Scheme 21: A genome editing system as described in any one of Implementation Schemes 1 to 20, wherein the cell genome does not contain an attachment site for installation.
[0046] Implementation Scheme 22: A method for integrating a sequence of interest into a cell genome, the method comprising contacting a cell with a genome editing system as described in any one of Implementation Schemes 1 to 21, such that the sequence of interest is integrated into the cell genome.
[0047] Implementation Scheme 23: A method for producing engineered cells, the method comprising contacting the cells with a genome editing system as described in any one of Implementation Schemes 1 to 21.
[0048] Implementation Scheme 24: A method for introducing a sequence of interest into a cell, the method comprising contacting the cell with a genome editing system as described in any one of Implementation Schemes 1 to 21.
[0049] Implementation Scheme 25: The method of any one of Implementation Schemes 22 to 24, wherein the cell is a mammalian cell, and optionally the cell is a human cell.
[0050] Implementation Scheme 26: The method as described in Implementation Scheme 25, wherein the cells are T cells, natural killer cells (NK cells), non-human embryonic stem cells, induced pluripotent stem cells (iPSCs), hematopoietic stem cells (HSCs), hepatocytes, muscle cells, monocytes, B cells, neurons, astrocytes, or microglia.
[0051] Implementation Scheme 27: The method as described in Implementation Scheme 26, wherein the cell is a T cell.
[0052] Implementation Scheme 28: The method of any one of Implementation Schemes 22 to 27, wherein the contact of the cells is in vivo.
[0053] Implementation Scheme 29: The method of any one of Implementation Schemes 22 to 27, wherein the contact of the cells is ex vivo.
[0054] Implementation Scheme 30: The method of any one of Implementation Schemes 22 to 29, wherein Cas or guide RNA is not used in the contact of the cells.
[0055] Implementation Scheme 31: The method of any one of Implementation Schemes 22 to 30, wherein the method does not include modifying the cell to insert the attachment site of the sequence of interest into the cell genome.
[0056] Implementation Scheme 32: An engineered cell comprising a genome editing system as described in any one of Implementation Schemes 1 to 21.
[0057] Implementation Scheme 33: Engineered cells as described in Implementation Scheme 32, wherein the cells are human cells.
[0058] Implementation Scheme 34: Engineered cells as described in Implementation Scheme 32 or 33, wherein the cells are T cells, natural killer cells (NK cells), non-human embryonic stem cells, induced pluripotent stem cells (iPSCs), hematopoietic stem cells (HSCs), hepatocytes, myocytes, monocytes, B cells, neurons, astrocytes, or microglia.
[0059] Implementation Scheme 35: A method for treating a disease in a subject, the method comprising administering to the subject a genome editing system as described in any one of Implementation Schemes 1 to 21 or engineered cells as described in any one of Implementation Schemes 32 to 34. Attached Figure Description
[0060] Figure 1A-1B The cssDNA construct with LSR Cp36 mRNA used in the experiment is shown. Figure 1AA schematic diagram of the cssDNA constructs “cssDNA5” and “cssDNA6” is shown. Figure 1B This is an agarose gel electrophoresis showing the purified construct at the expected size.
[0061] Figure 2A and 2B This shows the effect of cssDNA5 ( Figure 2A ) and cssDNA6 ( Figure 2B The immunogenicity of cssDNA was reduced in THP1-Dual cells compared to the dsDNA nanoparticle control.
[0062] Figures 3A-3B The percentage of integration in HEK293FT cells was determined by ddPCR using cssDNA constructs and LSR 1xFlag-Cp36 mRNA via reverse transfection with Lipofectamine 3000. Figure 3A The percentage of integration within the dose range is displayed; Figure 3B The comparison of the integration rates observed between cssDNA and dsDNA is shown, with dsDNA as the denominator.
[0063] Figure 4 The percentage of integration to the left and right of the integration site is shown in HEK293FT cells by ddPCR using cssDNA constructs and LSR 1xFlag-Cp36 mRNA determined by reverse transfection with Lipofectamine 3000.
[0064] Figure 5 The percentage of integration in primary T cells, determined by ddPCR using cssDNA and LSR 1xFlag-Cp36 mRNA via electroporation, is shown.
[0065] Figures 6A-6B The cssDNA construct with LSR BxB1 used in the experiment is shown. Figure 6A The construct design of "cssDNA8" is shown; Figure 6B The agarose gel electrophoresis of the CSSDNA shows purification at the expected size.
[0066] Figures 7A-7B The results showed the use of cssDNA and Lipofectamine 3000 in HEK293FT cells expressing BxB1 and having installed Bxb1 attachment sites. Figure 7A ) and Lipofectamine MessengerMAX ( Figure 7BThe percentage of integration on the left and right sides was determined by ddPCR during reverse transfection.
[0067] Figure 8 The percentage of integration on the left and right sides is shown by ddPCR using cssDNA and LNP in HEK293FT cells expressing BxB1 and having installed Bxb1 attachment sites.
[0068] Figure 9 The percentage of integration determined by ddPCR using cssDNA6 and 1xFlag-Cp36 plasmids is shown compared to cssDNA6 and 1xFlag-Cp36-2A-RAD51 plasmids in HEK293FT cells.
[0069] Figure 10 The structures of some known ionizable lipids are shown.
[0070] Figure 11 This study demonstrated that in primary human T cells, cssDNA, compared to double-stranded DNA or cGAMP, reduced the immunogenicity associated with the cGAS / STING pathway. Cells were harvested 1 hour after electroporation, and the levels of pTBK1, pIRF3, and pSTING were analyzed by Western blotting.
[0071] Figure 12 The study demonstrated LSR-mediated genome integration of the cssDNA donor template with the mRNA LSR variant in HEK293FT cells 48 hours post-transfection, as measured by ddPCR.
[0072] Figure 13A -B shows that electroporation of cssDNA and a variant LSR as mRNA led to CAR integration in primary human T cells. CAR expression in cells was evaluated by flow cytometry 7 days after electroporation. Figure 13A ), and CAR integration in cells was evaluated at four genomic integration sites using ddPCR. Figure 13B ).
[0073] Figure 14 Compared to nanoparticles, the delivery of cssDNA and a variant LSR as mRNA via LNP resulted in CAR-positive expression in human primary T cells by flow cytometry on day 7.
[0074] Figure 15A -D indicates the use of an oligonucleotide ( Figure 15A ) or an oligonucleotide containing locked nucleic acid ( Figure 15C Delivery of cssDNA and a variant LSR as mRNA, and respectively in Figure 15B and Figure 15DIntegration into HEK293FT cells was confirmed by ddPCR after transfection with Lipo3000.
[0075] Figure 16A -B shows the results obtained through flow cytometry ( Figure 16A ) or via ddPCR ( Figure 16B The integration of CD19-CAR with CD3-targeting LNPs, after incubation for 7 days with a co-encapsulated mRNA encoding an LSR variant and a cssDNA donor template encoding the CD19-CAR transgene, was evaluated, along with the expression efficiency of CD19-CAR in primary human T cells. The CD3-targeting LNPs encapsulated either only LSR mRNA, only the cssDNA donor template, or both LSR mRNA and the donor template cssDNA. Figure 16A The percentage of CAR+ T cells is shown. Figure 16B Integration in T cells was shown at four genomic loci (GS10, GS11, GS12, and GS13).
[0076] Figure 17A -F shows in vivo CD19-CAR T cell production and functional activity (B cell depletion) in humanized NSG mice that were given a co-encapsulated mRNA encoding an LSR variant and a cssDNA donor template encoding a CD19-CAR transgene. Figure 17A and Figure 17B The percentage of human B cells or T cells in total viable cells analyzed by flow cytometry in bone marrow, lymph nodes, or spleen recovered from terminal samples, 8 days after administration of CD3-targeted LNPs encapsulated with specified mRNA and / or cssDNA components to mice, respectively. Flow cytometry analysis of terminal tissues showed a significant reduction in B cells ( Figure 17A And T cells showed no significant changes. Figure 17B ). In the case of co-encapsulated LSR mRNA + cssDNA ( Figure 17C ) or only encapsulate CSSDNA ( Figure 17D Scatter plots of CAR expression (Y-axis) and forward scattering (X-axis) as evaluated by flow cytometry were displayed in spleen T cells of mice with CD3 targeting LNP. LSR-mediated CAR integration at four genomic loci (GS10, GS11, GS12, GS13) in terminal tissues (including blood (B), bone marrow (BM), lymph nodes (LN), or spleen (S)) was analyzed in terminal tissues by ddPCR and is expressed as the mean integration % across all mice within a cohort. Figure 17E Or expressed as the percentage of integration per individual mouse given a CD3-targeting LNP with an LSR mRNA and / or cssDNA donor template (as indicated) ( Figure 17F ).
[0077] Figure 18A -C shows that antitumor activity was achieved in vivo with integrated CD19-CAR T cells in NSG-MHCI / II-DKO mice in tests conducted with two different LSR variants (“LSR-A” and “LSR-B”). Compared to LNPs (hashed lines) that encapsulate only mRNA or DNA, CD3-targeted LNPs (solid circles) with co-encapsulated variant LSR mRNA and cssDNA encoding CD19 CAR were observed to have reduced tumor burden via IVIS imaging. Figure 18A CD19 CAR integration was observed in blood over time by ddPCR, and is shown as the percentage of integration of the first 8 integration sites at days 4 and 26. Figure 18B CD19-CAR-T cells were detected in the blood 10 days after LNP administration by flow cytometry. Figure 18C ).
[0078] Figure 19A -E showed that cssDNA injected into wild-type mice with LNP-encapsulated cGAS pathway-related immunogenicity was reduced in vivo compared to injection with nanoparticles or plasmids. The reduced immunogenicity was mediated by IL-6 (…). Figure 19A ), IFN-α ( Figure 19B ), IFN-β ( Figure 19C ) and MCP-1 ( Figure 19D The decrease in weight and no statistically significant change in body weight () Figure 19E (to prove it)
[0079] Figure 20A -B shows the test results for five ratios of cssDNA to LSRmRNA in co-encapsulated LNP formulations in primary T cells. Figure 20A CAR expression was shown, and Figure 20B The percentage of integration at the GS10 integration site is shown four days after LNP administration.
[0080] Figure 21A -E indicates that the cssDNA produced by the enzymatic conversion method is active as a template for LSR-mediated integration in primary T cells. Figure 21A This is a schematic diagram illustrating the process of converting double-stranded DNA into CSSDNA, and Figure 21B This is a schematic diagram of the starting plasmid used. Figure 21C The gel electrophoresis of the reaction products is shown. Figure 21D It is a chromatogram showing the elution of cssDNA as measured by OD260m. Figure 21EThe percentage of CSSDNA integration from primary T cells from the two donors is shown. Detailed Implementation
[0081] This document discloses nonviral compositions and systems for gene delivery and integration into cells. The inventors have unexpectedly determined that cssDNA delivered in LNPs can be used to successfully integrate sequences of interest into the cellular genome using LSRs and cssDNA containing AttD and the sequence of interest, and further determined that such integration can be achieved in primary T cells without triggering an immune response.
[0082] This disclosure provides compositions and gene editing systems comprising cssDNA and LSR in LNP formulations, which enable the insertion of sequences of interest into the cellular genome without the installation of attachment sites within the cellular genome. Such compositions and genome editing systems disclosed herein result in the expression of sequences of interest in cells.
[0083] This disclosure also provides methods for integrating a sequence of interest (e.g., a gene) from CSSDNA into the genome of a subject, treating a disease by integrating a sequence of interest (e.g., a gene) from CSSDNA into the genome of a subject, or generating engineered cells or cells expressing new proteins or having new functions by introducing a sequence of interest (e.g., a gene) from CSSDNA, which can be administered to a subject to treat a disease or condition using the genome editing system disclosed herein.
[0084] I. Definition
[0085] Unless otherwise stated, the following terms and phrases have the meanings described below. These definitions are not intended to be restrictive in nature and are intended to provide a clearer understanding of certain aspects of this disclosure.
[0086] AttA site: As used herein, the term "AttA site" refers to the attachment site within the cellular genome where LSRs bind. AttA sites can be present in the genomes of non-phage and non-bacterial organisms (e.g., humans).
[0087] Attachment site: As used herein, the term “attachment site” refers to a nucleic acid sequence to which an LSR binds and which facilitates recombination of a DNA sequence of interest.
[0088] AttD site: As used herein, the term "AttD site" refers to the attachment site in DNA where LSRs bind. AttD sites can be engineered into plasmid DNA to promote recombination of sequences of interest at homologous AttA sites.
[0089] Identity: As used herein, in the context of sequence comparison, the term "identity" refers to the number of exact matches between two distinct sequences in a sequence alignment. Sequence alignment techniques and software include basic local alignment search tools (BLAST, which includes, for example, BLASTP for protein sequences and BLASTN for nucleic acid sequences), ClustalOmega, MUSCLE, and MAFFT.
[0090] Isolated: As used in this article, an "isolated" LSR refers to an LSR or nucleic acid encoding an LSR that is not in its native phage or bacterial environment.
[0091] II. Compositions and Genome Editing Systems
[0092] This document discloses compositions and genome editing systems comprising cssDNA with a sequence of interest, which are used for: integrating the sequence of interest into cells (e.g., using an LSR as disclosed herein) for expressing a transgene or silencing a target gene (e.g., using a sequence of interest encoding miRNA or shRNA). In some embodiments, the sequence of interest encodes a chimeric antigen receptor (CAR). In particular, this document discloses compositions, systems, and methods for in vivo delivery of an LNP comprising a genome editing system for integrating the sequence of interest into cells. As illustrated in the embodiments herein, for example, in the case where the sequence of interest on the cssDNA encodes a CAR, administration of LSR mRNA and cssDNA co-encapsulated in an LNP formulation unexpectedly supports CAR-T levels sufficient to treat the disease. In some embodiments herein, the compositions, genome editing systems, or LNPs of this document exhibit reduced immunogenicity in treated subjects compared to dsDNA compositions, genome editing systems, or LNPs encoding sequences of interest.
[0093] In some embodiments, compositions are provided comprising (a) mRNA encoding LSR; (b) cssDNA containing AttD and the sequence of interest; (c) lipid nanoparticles; and optionally (d) additional components.
[0094] In some embodiments, the composition comprises (a) mRNA encoding LSR; (b) cssDNA containing AttD and the sequence of interest; and (c) lipid nanoparticles. In some embodiments, the sequence of interest encodes a treatment-related protein. In some embodiments, the sequence of interest encodes a CAR. In some embodiments, the cssDNA in the composition has reduced immunogenicity in subjects compared to compositions containing dsDNA encoding the sequence of interest. This reduced immunogenicity can be demonstrated by lower levels of inflammatory cytokines (such as IL-6, IFN-β, IFN-α, and / or MCP-1) and / or no significant change in body weight in subjects compared to those treated with compositions containing dsDNA encoding the sequence of interest. In some embodiments, the additional component (d) is absent. For example, in some embodiments, (a), (b), and (c) are present but (d) is absent. In some embodiments, the ratio of b) to a) is 3:1 to 1:3. In some embodiments, the ratio of b) to a) is 2:1 to 1:2. In some implementations, the ratio of b) to a) is 1:1.
[0095] In some embodiments, the genome editing system comprises a nucleic acid encoding a large serine recombinase (LSR) and cssDNA containing a donor attachment site (AttD) and a sequence of interest for the cell, wherein the sequence of interest is integrated into the cell genome. In some embodiments, the nucleic acid encoding the LSR is mRNA.
[0096] In some embodiments, the composition or genome editing system comprises a single lipid-based formulation containing mRNA encoding an LSR and cssDNA containing AttD and the sequence of interest (i.e., co-encapsulated). In some embodiments, the genome editing system comprises two lipid-based formulations, one containing mRNA encoding an LSR and the other containing cssDNA containing AttD and the sequence of interest (i.e., separately encapsulated). In some embodiments, the lipid-based formulation is an LNP. In some embodiments, the ratio of b) to a) in the genome editing system is 3:1 to 1:3. In some embodiments, the ratio of cssDNA to mRNA is 2:1 to 1:2. In some embodiments, the ratio of cssDNA to mRNA in the genome editing system is 1:1.
[0097] In some embodiments, the genome editing system includes an LSR, cssDNA containing AttD and the sequence of interest, and additional components. In some embodiments, the additional components enhance nuclear input of the cssDNA into the cell nucleus. For example, in some embodiments, the additional component is a single-stranded DNA-binding protein. In some embodiments, the additional component is a cis sequence element. In some embodiments, the additional component enhances the integration efficiency of the cssDNA by increasing the amount of double-stranded DNA formed from the cssDNA in the cell. In some embodiments, the additional component is a nucleic acid (e.g., an oligonucleotide) that increases the amount of double-stranded DNA formed from the cssDNA in the cell. In some embodiments, the additional component is an oligonucleotide. In some embodiments, the additional component is an antisense oligonucleotide. In some embodiments, the additional component is an oligonucleotide comprising modified nucleic acid, optionally in a locked form of DNA.
[0098] A. Large serine recombinase component
[0099] This disclosure provides compositions and genome editing systems for expressing and delivering mRNA encoding a large serine recombinase (LSR) and cssDNA containing an AttD site and a sequence of interest into cells to integrate the sequence of interest. As used herein, an LSR refers to a protein having the amino acid sequence of a naturally occurring LSR, as well as variants of such LSRs, including sequence modifications, mutants, deletions, conjugates, chemical modifications, LSR fusion proteins, truncations, etc. In some embodiments, the cssDNA and the mRNA encoding the LSR are sufficient to express the sequence of interest in cells, such that no additional components are required. In some embodiments, the LSR is a “genome-targeting LSR” (i.e., an LSR that can integrate DNA primarily at the integration site in the genome without any attached attachment site). Therefore, in some embodiments, the LSR is not a “landing pad LSR” (i.e., an LSR that requires modification of the cell to insert an attachment site as the primary site for integration into the cellular genome).
[0100] Suitable LSRs for the disclosed genome editing systems may include LSRs known in the art, including, for example, Pa01, Bxb1, PhiC31, Pf80, Cp36, Dn29, BceINTa, SscINTd, SacINTd, INT10, Dre, Vika, Bxbl, ΦpC31, RDF, ΦBTl, R1, R2, R3, R4, R5, TP901-1, Al18, ΦFCl, ΦCl, MR11, TGI, Φ370.1, Wβ, BL3, SPBc, K38, or variants thereof. See, for example, Durrant et al., Nature Biotechnology 41, 488-499 (2023); Yarnall et al., Nature Biotechnology 41, 500-512 (2023); Xu et al., BMC Biotechnol, 13, 87 (2013). In some embodiments, the genome editing system includes a latex recombinant recombinant sensor (LSR). In some embodiments, the genome editing system includes an LSR that exhibits genome integration activity.
[0101] In some embodiments, LSRs exhibit recombination activity in mammalian cells. In certain cases, recombination activity results in the integration of the sequence of interest into the genome of the mammalian cell. In some embodiments, the mammalian cells are non-human mammalian cells (e.g., mouse, rat, or non-human primate cells). In some embodiments, the mammalian cells are human cells. Assays used to determine the recombination activity of LSRs can be performed using a variety of methods. For example, assays involving the introduction of reporter molecules into cells (e.g., to induce fluorescence in cells) via LSR recombination plasmids can demonstrate whether the LSR has activity with a pair of attachment sites. These recombination events can be evaluated by, for example, flow cytometry or fluorescence microscopy, both techniques known in the art. Flow cytometry instruments include Attune (Thermo Fisher Scientific), ID7000 Spectroscopic Cell Analyzer (Sony), BD FACSymphony (BDBiosciences), and CytoFLEX (Beckman Coulter). Fluorescence microscopy includes EVOS fluorescence microscopy (Thermo Fisher Scientific), Eclipse fluorescence microscopy (Nikon), and Axiovert fluorescence microscopy (Zeiss). Recombinant activity can be evaluated by comparison with negative control conditions (e.g., without LSR).
[0102] Another approach for assessing LSR activity involves providing cells with the LSR and DNA containing the relevant AttD site (e.g., cssDNA), and determining whether the sequence of interest from that DNA has been integrated into the genome. The resulting integration event can be measured, for example, by nucleic acid quantification or nucleic acid sequencing. Nucleic acid quantification can be performed using droplet digital PCR (ddPCR) and suitable nucleic acid quantification kits or instruments. Non-limiting examples include the Qubit BR dsDNA assay (Thermo Fisher Scientific), the Qubit HS dsDNA assay (Thermo Fisher Scientific), the Nanodrop spectrophotometer (Thermo Fisher Scientific), the Stunner spectrophotometer (Unchained Labs), and the Lunatic spectrophotometer (Unchained Labs). Nucleic acid sequencing can be performed using NextSeq (Ilumina), GridION (Oxford Nanopore Technologies), the Revio System (Pacific Biosciences), and others.
[0103] In some embodiments, the LSR is capable of integrating sequences from nucleic acids (e.g., CSSDNA) into chromosomal locations within the genome. In some embodiments, the LSR is capable of integrating sequences from nucleic acids into multiple chromosomal locations within the genome. In some embodiments, the LSR can integrate sequences from nucleic acids into chromosomal locations that are non-coding DNA. In some embodiments, the LSR can integrate sequences from nucleic acids into chromosomal locations that have endogenous promoters. In some embodiments, the LSR can integrate sequences from nucleic acids into chromosomal locations with high transcriptional activity. In some embodiments, the LSR can integrate sequences from nucleic acids into chromosomal locations with tissue- or cell-type-specific regulation of gene expression. In some embodiments, the LSR can integrate sequences from nucleic acids into genes to produce non-functional gene products. In some embodiments, the LSR can integrate sequences from nucleic acids into chromosomal locations to disrupt interactions between cis-regulatory transcriptional elements.
[0104] In some embodiments, the LSR of the genome editing system contains a nuclear localization signal (“NLS”). In some embodiments, the nuclear localization signal is not natural for the LSR. In some embodiments, the LSR contains more than one NLS. In some embodiments, the LSR contains two NLSs. In some embodiments, the LSR contains three NLSs. In some embodiments, the LSR contains more than three NLSs. In some embodiments, the NLS is derived from SV40. In some embodiments, the NLS is derived from myc. In some embodiments, the NLS is derived from p53. Exemplary sequences of NLS are known in the art. See, for example, Lu et al., Cell Communication and Signaling 19, 60 (2021).
[0105] In some embodiments, the genome editing system includes a fusion protein comprising an LSR and a fusion domain (referred to herein as an "LSR-fusion protein"). In some embodiments, the fusion domain comprises, for example, a peptide to which the LSR is not naturally linked. In some embodiments, the fusion domain comprises, for example, a protein domain to which the LSR is not naturally linked. In some embodiments, the fusion domain comprises, for example, a protein to which the LSR is not naturally linked. In some embodiments, the fusion domain comprises a cell-penetrating peptide. In some embodiments, the fusion domain comprises an arginine-rich peptide. In some embodiments, the fusion domain comprises an arginine-rich dipeptide repeat. In some embodiments, the fusion domain comprises a combination of a DNA-binding domain, a cell-penetrating peptide, an arginine-rich peptide, and an arginine-rich dipeptide repeat. In some embodiments, the LSR of the genome editing system is fused to a DNA-binding domain. In some embodiments, the DNA-binding domain comprises a catalytically inactive Cas polypeptide (dCas). In some embodiments, dCas comprises dCas9 or dCas12. In some embodiments, the DNA-binding domain comprises a catalytically inactive zinc finger polypeptide (ZNF). In some embodiments, the DNA-binding domain comprises a non-catalytically active transcription activator-like effector nuclease (TALEN). In some embodiments, the LSR fusion protein comprises a linker between the LSR and the fusion domain. In some embodiments, the LSR fusion protein does not comprise a linker between the LSR and the fusion domain. In each case, the genome editing system comprises mRNA encoding such an LSR fusion protein.
[0106] In some implementations, the LSR is encoded by mRNA. In some implementations, the LSR is encoded by self-amplifying RNA (saRNA). In some implementations, the LSR is encoded by circular RNA.
[0107] In some embodiments, the LSR comprises the amino acid sequence of SEQ ID NO: 2024 or a sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity with the amino acid sequence of SEQ ID NO: 2024.
[0108] In some embodiments, the LSR contains the amino acid sequence of SEQ ID NO: 2029 or a sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity with the amino acid sequence of SEQ ID NO: 2029.
[0109] In some embodiments, the LSR comprises the amino acid sequence of SEQ ID NO: 2030 or a sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity with the amino acid sequence of SEQ ID NO: 2030.
[0110] In some embodiments, the mRNA contains a 5' cap structure or a modified 5' cap structure. In some embodiments, the mRNA contains a 5' untranslated region (UTR). In some embodiments, the mRNA contains a 3' UTR. In some embodiments, the UTR contains one or more viral internal ribosome entry sites (IRES) or eukaryotic IRES. In some embodiments, the mRNA contains a miRNA binding site or a fragment thereof, a restriction site or a fragment thereof, an RNA editing motif or a fragment thereof, a zip-coding element or a fragment thereof, an RNA transport element or a fragment thereof, or a combination thereof. In some embodiments, the accessory element contains a binding domain for an IRES trans-acting factor (ITAF). In some embodiments, the mRNA contains a cis-regulatory element. In some embodiments, the cis-regulatory element acts as a safety switch for regulating the expression of the integrated sequence. In some embodiments, the cis-regulatory element is a miRNA binding site. In some embodiments, the cis-regulatory element is a conditional activator. In some embodiments, the cis-regulatory element is a repressor. In some embodiments, the cis-regulatory element is an adenosine deaminase (ADAR) enzyme that acts on RNA. In some implementations, the mRNA comprises a polyA region, a polyC region, a polyAC region, a polypyrimidine bundle, or a combination or variant thereof.
[0111] The LSRs of the genome editing systems disclosed herein can be prepared using suitable methods known in the art. In some embodiments, mRNA is prepared by in vitro transcription.
[0112] B. Circular single-stranded DNA components
[0113] The compositions and CSSDNA of the genome editing systems disclosed herein can be prepared using suitable methods known in the art, including in vitro synthesis or generation using phage particles in bacterial systems. See, for example, Nafisi et al., Synthetic Biology 3(1): ysy015 (2018); Cha et al., Advanced Functional Materials:2010867 (2021); Iyer et al., CRISPR J 5(5):685-701 (2022); Shepherd et al., Scientific Reports 9: 6121 (2019). Methods for in vitro synthesis include enzymatic methods, including the use of, for example, polymerase chain reaction, rolling circle amplification, environment-ligation mediated amplification, and isothermal amplification and strand displacement.
[0114] In some embodiments, the cssDNA does not contain a sequence from the f1 origin of replication. In some embodiments, the cssDNA contains a sequence from the f1 origin of replication. In some embodiments, the cssDNA does not contain an antibiotic resistance gene. In some embodiments, the cssDNA contains an antibiotic resistance gene. In some embodiments, the cssDNA does not contain a sequence from the bacterial origin of replication. In some embodiments, the cssDNA contains a sequence from the bacterial origin of replication. In some embodiments, the cssDNA does not contain a packaging signal. In some embodiments, the cssDNA contains a packaging signal. In some embodiments, the phage particle sequence is removed from the cssDNA.
[0115] In some embodiments, CSSDNA is purified to reduce the level of endotoxins produced by the preparation in bacterial cells. In some embodiments, the endotoxin level of the CSSDNA is less than 0.1 EU / µg, 0.05 EU / µg, 0.01 EU / µg, or 0.005 EU / µg. In some embodiments, the endotoxin level of the CSSDNA is less than 0.1 EU / µg. In some embodiments, the endotoxin level of the CSSDNA is less than 0.05 EU / µg. In some embodiments, the endotoxin level of the CSSDNA is less than 0.01 EU / µg. In some embodiments, the endotoxin level of the CSSDNA is less than 0.005 EU / µg. The endotoxin level of the CSSDNA disclosed herein can be reduced using commercially available kits and filtration methods. In some embodiments, the Norgen Biotek Endotoxin Removal Kit is used for optimal reduction of the endotoxin level of the CSSDNA.
[0116] In some embodiments, CSSDNA is generated from dsDNA using an enzymatic conversion method. See, for example, Tang et al., Nature Communications 14: 6665 (2023). The dsDNA starting material can be a plasmid or a nanoparticle. In some embodiments, the CSSDNA used herein is generated from a dsDNA plasmid or nanoparticle containing the BbvCI site. The dsDNA is cleaved and then degraded with an exonuclease to produce CSSDNA that can be purified using column purification methods.
[0117] In some embodiments, cssDNA encodes a DNA nuclear targeting sequence (DTS). In some embodiments, the DTS is an enhancer region derived from SV40. The sequence of the DTS is known in the art and includes, for example, SV40, NFκB, and GRE.
[0118] In some embodiments, the disclosed compositions and genome editing systems contain about 0.3 to 20 kb of cssDNA. In some embodiments, the cssDNA contains about 0.3 to 20 kb, 0.4 to 20 kb, 0.5 to 20 kb, 0.6 to 20 kb, 0.7 to 20 kb, 0.8 to 20 kb, 0.9 to 20 kb, 1.0 to 20 kb, 1.1 to 20 kb, 1.2 to 20 kb, 1.3 to 20 kb, 1.4 to 20 kb, or 1.5 to 20 kb. In some implementations, cssDNA comprises approximately 1.6 to 2 kb, 1.6 to 3 kb, 1.6 to 4 kb, 1.6 to 5 kb, 1.6 to 6 kb, 1.6 to 7 kb, 1.6 to 8 kb, 1.6 to 9 kb, 1.6 to 10 kb, 1.6 to 11 kb, 1.6 to 12 kb, 1.6 to 13 kb, 1.6 to 14 kb, 1.6 to 15 kb, 1.6 to 16 kb, 1.6 to 17 kb, 1.6 to 18 kb, 1.6 to 19 kb, 1.6 to 20 kb, 2 to 3 kb, 2 to 4 kb, 2 to 5 kb, 2 to 6 kb, 2 to 7 kb, 2 to 8 kb, 2 to 9 kb, 2 to 10 kb, 2 to 11 kb, 2 to 12 kb, 2 to 13 kb, etc. kb, 2 to 14 kb, 2 to 15 kb, 2 to 16 kb, 2 to 17 kb, 2 to 18 kb, 2 to 19 kb, 2 to 20 kb, 3 to 4 kb, 3 to 5 kb, 3 to 6 kb, 3 to 7 kb, 3 to 8 kb, 3 to 9 kb, 3 to 10 kb, 3 to 11 kb, 3 to 12 kb, 3 to 13 kb, 3 to 14 kb, 3 to 15 kb, 3 to 16 kb, 3 to 17 kb, 3 to 18 kb, 3 to 19 kb, or 3 to 20 kb.
[0119] In some embodiments, the cssDNA contains about 5 to 13 kb. In some embodiments, the cssDNA contains about 5 to 10 kb. In some embodiments, the cssDNA contains about 5 to 9 kb. In some embodiments, the cssDNA contains about 5 to 8 kb. In some embodiments, the cssDNA contains about 5 to 7 kb. In some embodiments, the cssDNA contains about 5 to 6 kb.
[0120] 1. AttD site
[0121] In some embodiments, the cssDNA component of the compositions and genome editing systems contains an AttD site. The LSRs of the disclosed compositions and genome editing systems can be associated with one or more pairs of associated homologous attachment sites (AttD sites and AttA sites). Specifically, a given LSR can facilitate cssDNA integration by “pairing” its associated AttD site with a homologous AttA site in the cellular genome. In the compositions and genome editing systems covered herein, the cssDNA contains an AttD site that will work in conjunction with the LSR to integrate the sequence of interest into the cellular genome.
[0122] In some embodiments, the cssDNA contains more than one AttD site (i.e., an "array" of" AttDs). In some embodiments, the cssDNA contains two AttDs. In some embodiments, the cssDNA contains three AttDs. In some embodiments, the cssDNA contains four AttDs. In some embodiments, the cssDNA contains five AttDs. In some embodiments, the cssDNA contains six AttDs. In some embodiments, the cssDNA contains seven AttDs. In some embodiments, the cssDNA contains eight AttDs. In some embodiments, the cssDNA contains nine AttDs. In some embodiments, the cssDNA contains ten AttDs.
[0123] In some embodiments, the LSR disclosed herein binds to or is capable of binding to attachment sites comprising 80 nucleotides (nt). In some embodiments, the LSR is capable of binding to homologous attachment sites of varying lengths. In some embodiments, at least one attachment site contains a sequence of less than 80 nt. In some embodiments, each homologous attachment site contains 80 nt. In some embodiments, each homologous attachment site contains less than 80 nt. In some embodiments, at least one attachment site contains a 52 nt sequence. In some embodiments, at least one attachment site contains a 48 nt sequence (Ghosh et al., (2003) Mol. Cell 12(5):1101-11). In some embodiments, at least one attachment site contains a 39 nt sequence (Groth et al., (2000) Proc. Natl. Acad. Sci. USA 97(11):5995-6000). In some embodiments, at least one attachment site comprises a 36 nt sequence (Ghosh et al., (2003) Mol. Cell 12(5):1101-11). In some embodiments, at least one attachment site comprises a 34 nt sequence (Groth et al., (2000) Proc. Natl. Acad. Sci. USA 97(11):5995-6000). In some embodiments, at least one attachment site comprises a 26 nt sequence (Durrant et al., (2022) Nat. Biotechnol. 41(4):488-99). In some embodiments, the AttD site comprises fewer nucleotides than the AttA site. In some embodiments, the AttD site comprises more nucleotides than the AttA site. In some embodiments, the AttD site comprises at least 26, 34, 36, 39, 48, or 52 nucleotides, wherein these nucleotides comprise a dinucleotide core and an even number of nucleotides directly adjacent to the dinucleotide core on either side. In some embodiments, the AttD site contains the nucleotide sequence of SEQ ID NO: 2025 or contains a sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity with the nucleotide sequence of SEQ ID NO: 2025.
[0124] In some embodiments, the AttD site comprises an AttP site. In some embodiments, the AttD site comprises a modified AttP site. In some embodiments, the modified AttP site has been optimized for a mammalian genome. In some embodiments, the mammalian genome is a non-human genome (e.g., a mouse, rat, or non-human primate genome). In some embodiments, the mammalian genome is a human genome. In some embodiments, the modified AttP site comprises a modified dinucleotide core. In some embodiments, the modified AttP site comprises modifications to both the dinucleotide core and the sequence outside the dinucleotide core.
[0125] In some embodiments, the AttD site comprises an AttB site. In some embodiments, the AttD site comprises a modified AttB site. In some embodiments, the modified AttB site has been optimized for a mammalian genome. In some embodiments, the mammalian genome is a non-human genome (e.g., a mouse, rat, or non-human primate genome). In some embodiments, the mammalian genome is a human genome. In some embodiments, the modified AttB site comprises a modified dinucleotide core. In some embodiments, the modified AttB site comprises modifications to both the dinucleotide core and the sequence outside the dinucleotide core.
[0126] 2. Sequences of interest
[0127] In some embodiments, the cssDNA component of the composition or genome editing system comprises a sequence encoding one or more sequences of interest for integration into the cellular genome. In some embodiments, the sequence of interest is a non-coding sequence. In some embodiments, the sequence of interest is a coding sequence. In some embodiments, the sequence of interest is a gene or a portion of a gene (i.e., a portion of a gene encoding a specific domain of a protein, or an open reading frame of a protein or protein domain derived from a gene, an exon of a gene, or a series of exons of a gene, or a cDNA sequence encoding a protein, wherein that portion of the gene is functionally relevant). In some embodiments, the sequence of interest is a variant of a gene. In some embodiments, the sequence of interest encodes a protein, peptide, or polypeptide. In some embodiments, the sequence of interest encodes a transcriptional or translational control element (e.g., a promoter element, activator sequence, repressor sequence). In some embodiments, the sequence of interest encodes a secreted protein. In some embodiments, the sequence of interest comprises a sequence encoding a therapeutic protein (i.e., a protein that can be used as a therapeutic agent to treat, manage, or prevent disease). In some embodiments, the sequence of interest encodes therapeutic RNA. In some embodiments, the sequence of interest comprises one or more sequences encoding transcriptional or translational control elements and sequences encoding therapeutic proteins. In some embodiments, the sequence of interest comprises one or more sequences encoding transcriptional or translational control elements and sequences encoding therapeutic RNA. In some embodiments, the sequence encodes miRNA. In some embodiments, the sequence encodes shRNA. In some embodiments, the sequence encodes circRNA.
[0128] In some embodiments, the sequence of interest comprises a sequence encoding a guide RNA. In some embodiments, the sequence of interest comprises a sequence encoding a guide RNA for a DNA-based Cas system (e.g., Cas9). In some embodiments, the sequence of interest comprises a sequence encoding a guide RNA for an RNA-based Cas system (e.g., Cas13). See, for example, Ding et al., Nature Communications 15: 1572 (2024). In some embodiments, the sequence of interest comprises a sequence encoding a microRNA. In some embodiments, the sequence of interest comprises a sequence encoding a tRNA. In some embodiments, the sequence of interest comprises a sequence encoding a long non-coding RNA (lncRNA). In some embodiments, the sequence of interest comprises a sequence encoding a circular RNA.
[0129] In some embodiments, the sequence of interest encodes a secreted protein. In some embodiments, the sequence of interest encodes a membrane-bound protein. In some embodiments, the sequence of interest encodes a coagulation factor. In some embodiments, the sequence of interest encodes a cytokine. In some embodiments, the sequence of interest encodes a hormone. In some embodiments, the sequence of interest encodes an enzyme. In some embodiments, the sequence of interest encodes an antibody or a portion thereof. In some embodiments, the sequence of interest encodes a chimeric antigen receptor (CAR). In some embodiments, the sequence of interest encodes a T-cell receptor (TCR). In some embodiments, the sequence of interest encodes a B-cell receptor (BCR). In some embodiments, the sequence of interest encodes an immune cell activation or inhibition receptor. In some embodiments, the sequence of interest encodes a growth factor ligand. In some embodiments, the sequence of interest encodes a transcription factor. In some embodiments, the sequence of interest encodes a checkpoint inhibitor or agonist.
[0130] In some cases, the term "transgenic" is used in this document to refer to sequences of interest intended for integration into the cell's genome.
[0131] In some embodiments, the cssDNA contains the sequence of interest and also contains a promoter for expressing the sequence of interest. In some embodiments, the promoter is a constitutive promoter. In some embodiments, the promoter is an inducible promoter. In some embodiments, the promoter is a tissue-specific promoter. In some embodiments, the promoter is derived from a virus. In some embodiments, the promoter is derived from a mammal. In some embodiments, the promoter is a synthetic promoter. Suitable promoters are known in the art and can be used in the genome editing systems described herein. Non-limiting examples of promoters include chicken β-actin (CBA), CMV early enhancer / chicken β-actin (sCAG), human cytomegalovirus (hCMV), human synaptic protein (hSYN), spleen focal formation virus (SFFV), human polypeptide chain elongation factor (EF1α), phosphoglycerate kinase (PGK), ubiquitin C (UbiC), insulin promoter, CASI, and human α-1-antitrypsin promoter.
[0132] In some embodiments, the sequence of interest in the cssDNA comprises about 0.3 to 20 kb. In some embodiments, the sequence of interest in the cssDNA comprises about 0.3 to 20 kb, 0.4 to 20 kb, 0.5 to 20 kb, 0.6 to 20 kb, 0.7 to 20 kb, 0.8 to 20 kb, 0.9 to 20 kb, 1.0 to 20 kb, 1.1 to 20 kb, 1.2 to 20 kb, 1.3 to 20 kb, 1.4 to 20 kb, or 1.5 to 20 kb. In some implementations, the sequences of interest for cssDNA include approximately 1.6 to 2 kb, 1.6 to 3 kb, 1.6 to 4 kb, 1.6 to 5 kb, 1.6 to 6 kb, 1.6 to 7 kb, 1.6 to 8 kb, 1.6 to 9 kb, 1.6 to 10 kb, 1.6 to 11 kb, 1.6 to 12 kb, 1.6 to 13 kb, 1.6 to 14 kb, 1.6 to 15 kb, 1.6 to 16 kb, 1.6 to 17 kb, 1.6 to 18 kb, 1.6 to 19 kb, 1.6 to 20 kb, 2 to 3 kb, 2 to 4 kb, 2 to 5 kb, 2 to 6 kb, 2 to 7 kb, 2 to 8 kb, 2 to 9 kb, 2 to 10 kb, 2 to 11 kb, 2 to 12 kb, and 2 to 13 kb. kb, 2 to 14 kb, 2 to 15 kb, 2 to 16 kb, 2 to 17 kb, 2 to 18 kb, 2 to 19 kb, 2 to 20 kb, 3 to 4 kb, 3 to 5 kb, 3 to 6 kb, 3 to 7 kb, 3 to 8 kb, 3 to 9 kb, 3 to 10 kb, 3 to 11 kb, 3 to 12 kb, 3 to 13 kb, 3 to 14 kb, 3 to 15 kb, 3 to 16 kb, 3 to 17 kb, 3 to 18 kb, 3 to 19 kb, or 3 to 20 kb.
[0133] In some embodiments, the cssDNA contains about 5 to 13 kb. In some embodiments, the cssDNA contains about 5 to 10 kb. In some embodiments, the cssDNA contains about 5 to 9 kb. In some embodiments, the cssDNA contains about 5 to 8 kb. In some embodiments, the cssDNA contains about 5 to 7 kb. In some embodiments, the cssDNA contains about 5 to 6 kb.
[0134] C. Lipid-based formulations
[0135] In some embodiments, the composition or genome editing system comprises a lipid-based formulation (e.g., lipid nanoparticles) comprising cationic lipids, cofactor lipids, cholesterol / sterols, and PEG lipids. In some embodiments, the cationic lipids (also referred to herein as ionizable lipids) may comprise any cationic lipid known in the art that can be used in lipid-based formulations for delivering nucleic acids (RNA or DNA) to cells. In some embodiments, the ionizable lipids comprise DLin-MC3-DMA, SM-102, ALC-0315, DOTAP, Lipid 5, LP01, CKK-E12, OF-02, ATX001, ATX100, L319, CL1, TCL053, C24, SSPalmO-Phe, C14-4, A9, MC2, DODMA, DLin-DMA, or 9A1P9 (see...). Figure 10 ).
[0136] In some embodiments, the co-adjuvant lipid may include any co-adjuvant lipid known in the art that can be used in lipid-based formulations for delivering nucleic acids (RNA or DNA) into cells. In some embodiments, the co-adjuvant lipid is DSPC, DOPE, POPC, DOPC, or sphingomyelin.
[0137] In some embodiments, the sterol / cholesterol may include any sterol / cholesterol known in the art for use in lipid-based formulations for delivering nucleic acids (RNA or DNA) into cells. In some embodiments, the sterol / cholesterol is cholesterol, β-sitosterol, sitosterol, or DC cholesterol.
[0138] In some embodiments, the PEG-lipid may comprise any PEG lipid known in the art for use in lipid-based formulations for delivering nucleic acids (RNA or DNA) to cells. In some embodiments, the PEG-lipid comprises DMG-PEG, DPG-PEG, DSG-PEG, ALC-0159, PEG, DSPE-PEG, DSPE-PEG-X (where X is a small molecule), C14-PEG, C16-PEG, or C18-PEG. In some embodiments, the PEG molecular weight may vary between 500 Da and 10000 Da. In some embodiments, the PEG molecular weight is between 500 Da and 4000 Da. In some embodiments, the PEG molecular weight is between 2000 Da and 4000 Da. In some embodiments, the PEG molecular weight is between 2000 Da and 3500 Da.
[0139] In some embodiments, the lipid-based formulation comprises approximately 20%-70% ionizable lipids, approximately 5%-40% cofactor lipids, approximately 10%-70% cholesterol, and approximately 0.5%-10% PEG lipids, wherein the total percentage is equal to 100%. In some embodiments, the lipid-based formulation comprises approximately 35%-50% ionizable lipids, approximately 10%-20% cofactor lipids, approximately 28%-48% cholesterol, and approximately 1%-5% PEG lipids, wherein the total percentage is equal to 100%. In some embodiments, the lipid-based formulation comprises approximately 35%-50% ionizable lipids, approximately 10%-20% cofactor lipids, approximately 28%-48% cholesterol, and approximately 2% PEG lipids, wherein the total percentage is equal to 100%. In some embodiments, the lipid-based formulation comprises approximately 50% ionizable lipids, approximately 10% cofactor lipids, approximately 38% cholesterol, and approximately 2% PEG-lipids. In some embodiments, the lipid-based formulation comprises about 35% ionizable lipids, about 16% cofactor lipids, about 47% cholesterol, and about 2% PEG-lipids. In some embodiments, the lipid-based formulation comprises about 50% ionizable lipids, about 20% cofactor lipids, about 28% cholesterol, and about 2% PEG-lipids. In some embodiments, the lipid-based formulation comprises between 35% and 50% ionizable lipids, about 15% and 25% cofactor lipids, about 23% and 40% cholesterol, and about 1% and 5% PEG-lipids, wherein the total percentage is equal to 100%. In some embodiments, the lipid-based formulation comprises between 45% and 50% ionizable lipids, about 20% and 22% cofactor lipids, about 23% and 28% cholesterol, and about 2% and 3% PEG-lipids, wherein the total percentage is equal to 100%. In some embodiments, the lipid-based formulation comprises 50% ionizable lipids, 22% cofactor lipids, 25% cholesterol, and about 3% PEG-lipids, wherein the total percentage is equal to 100%. In some embodiments, the PEG lipid % in the lipid-based formulation comprises modified PEG lipids (i.e., chemically modified PEG lipid molecules). In some embodiments, the PEG lipid % in the lipid-based formulation comprises both unmodified PEG lipids and modified PEG lipids.
[0140] In some embodiments, the lipid-based formulation is lipid nanoparticles (LNPs). In some embodiments, the lipid-based formulation is a lipid complex (lipoplex). In some embodiments, the lipid-based formulation is a liposome.
[0141] In some embodiments, the lipid-based formulation has a size of about 50-250 nm. In some embodiments, the lipid-based formulation has a size of about 50-100 nm, 50-150 nm, 50-200 nm, or 50-250 nm. In some embodiments where two formulations are in a genome editing system, the formulations can be the same or different sizes. In some embodiments, at least one lipid-based formulation has a size of about 50 nm, 55 nm, 60 nm, 65 nm, 70 nm, 75 nm, 80 nm, 85 nm, 90 nm, 95 nm, 100 nm, 105 nm, 110 nm, 115 nm, 120 nm, 125 nm, 130 nm, 135 nm, 140 nm, 145 nm, 150 nm, 155 nm, 160 nm, 165 nm, 170 nm, 175 nm, 180 nm, 185 nm, 190 nm, 195 nm, 200 nm, 205 nm, 210 nm, 220 nm, 225 nm, 230 nm, 235 nm, 240 nm, 245 nm, or 250 nm.
[0142] In some embodiments, the lipid-based formulation further comprises a peptide. In some embodiments, the lipid-based formulation comprises a targeting moiety. In some embodiments, the targeting moiety is a peptide (e.g., an antibody or antibody fragment). In some embodiments, the lipid-based formulation further comprises a small molecule, peptide, or oligonucleotide (e.g., siRNA or ASO) encapsulated within the formulation. In some embodiments, the targeting moiety is a small molecule.
[0143] In some embodiments, the targeting portion is an antibody or antibody fragment. In some embodiments, the targeting portion is a bispecific antibody or bispecific antibody fragment. In some embodiments, the targeting portion is Fab. In some embodiments, the targeting portion is scFv. In some embodiments, the targeting portion is a nanobody. In some embodiments, the targeting portion is an antibody or antibody fragment that binds to CD3, CD4, CD5, or CD8. In some embodiments, the targeting portion is an N-acetylgalactosamine (GalNAc) targeting ligand. In some embodiments, the lipid-based formulation comprises GalNAc lipids. In some embodiments, the targeting portion targets the lipid-based formulation to T cells. In some embodiments, the targeting portion targets the lipid-based formulation to live cells.
[0144] D. Other components
[0145] In some embodiments, the composition or genome editing system further comprises additional components that enhance CSSDNA integration. In other embodiments, such additional components are not included. In some embodiments, where present, the additional components enhance CSSDNA integration by increasing the input of CSSDNA into the cell nucleus. In some embodiments, the additional components enhance CSSDNA integration by increasing the input of CSSDNA from LNPs into the cell nucleus. In some embodiments, the additional components enhance CSSDNA integration by increasing the formation of double-stranded DNA from CSSDNA within the cell.
[0146] This enhanced integration can be measured, for example, by ddPCR and reported as the percentage of integration at the integration site in the cellular genome. Compared to genome editing systems without additional components, the increase in nuclear input can be measured by in situ hybridization (ISH) or transgene expression (i.e., expression of the sequence of interest). Compared to genome editing systems without additional components, the increase in double-strand formation can be measured using in situ hybridization (ISH) and probes designed to bind to double-stranded DNA.
[0147] In some embodiments, the composition or genome editing system further comprises a nucleic acid encoding a single-stranded DNA-binding protein. In some embodiments, the mRNA encodes a single-stranded DNA-binding protein. In some embodiments, the mRNA encodes a single-stranded DNA-binding protein as a fusion with an LSR. In some embodiments, the mRNA encodes a single-stranded DNA-binding protein that is not a fusion with an LSR. In some embodiments, the single-stranded DNA-binding protein is a nucleic acid separate from the mRNA LSR. In some embodiments, the single-stranded DNA-binding protein is a separate mRNA. In some embodiments, the single-stranded DNA-binding protein is a separate DNA. In some embodiments, the single-stranded DNA-binding protein is a protein. In some embodiments, the single-stranded DNA-binding protein comprises one or more NLSs. Non-limiting examples of single-stranded DNA-binding proteins include replication protein A (e.g., RPA1, RP2, or RPA3), Rad51, DMC1, single-stranded DNA-binding protein (SSB), RecA, UvxX, UvsY, NS1, SV40 large T antigen, E1, E2, and DNA-dependent protein kinases (DNA-PK). In some embodiments, the single-stranded DNA-binding protein is a natural protein. In some embodiments, the single-stranded DNA-binding protein is synthetically designed. In some embodiments, the single-stranded DNA-binding protein is a synthetic protein containing an OB-sheet nucleic acid-binding domain (including, for example, SSB, ExoI, RecO, RecJ, RecG, PriA, Pol II, RuvA, RPA, hSSB, CTC1, STN1, POT1, TPP1, TAP82, BRCA2, DNA ligase 4, MCM). See, for example, Bianco, Front. Mol. Biosci. 9: 784451 (2022).
[0148] In some embodiments, the composition or genome editing system further comprises, for example, a cis-sequence element that enhances nuclear input to CSSDNA. In some embodiments, the CSSDNA encodes the cis-sequence element. In some embodiments, the cis-sequence element is a nucleic acid separate from the CSSDNA. In some embodiments, the cis-sequence element is a separate DNA. Non-limiting examples of cis-sequence elements include G tetrads, aptamers, or AARTs. In some embodiments, an additional component is a single-stranded DNA aptamer. In some embodiments, the DNA aptamer binds to HMGB1.
[0149] In some embodiments, the composition or genome editing system further comprises nucleic acids that increase the double-strand formation of CSSDNA in the cell. In some embodiments, the nucleic acid is DNA. In some embodiments, the nucleic acid is modified DNA. In some embodiments, the nucleic acid is an oligonucleotide. In some embodiments, the nucleic acid is a locked form of DNA. In some embodiments, the nucleic acid has a 3' hydroxyl group. In some embodiments, the nucleic acid is 40 nucleotides. In some embodiments, the nucleic acid is less than 40 nucleotides. In some embodiments, the nucleic acid is less than 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 25, or 20 nucleotides. In some embodiments, the nucleic acid is 40 to 90 nucleotides. In some embodiments, the nucleic acid is 40 to 80 nucleotides. In some embodiments, the nucleic acid is 40 to 70 nucleotides. In some embodiments, the nucleic acid is 40 to 60 nucleotides. In some embodiments, the nucleic acid is 40 to 50 nucleotides. In some embodiments, the nucleic acid is an antisense oligonucleotide. In some implementation schemes, nucleic acids are sense oligonucleotides.
[0150] In some embodiments, an additional component is an oligonucleotide comprising a modified nucleic acid. In some embodiments, an additional component is an oligonucleotide comprising locked DNA. In some embodiments, the oligonucleotide hybridizes with cssDNA and comprises locked DNA (also known as locked nucleic acid or LNA). In some embodiments, the modified nucleic acid is an LNA. In some embodiments, the modified nucleic acid is selected from any of the following: phosphate thioester, 2'O-methyl, 2'-fluoro, 2',2'-methoxyethyl (MOE), phosphorodiamidate morpholinooligomer (PMO), cEt (restricted ethyl-bridged nucleic acid), ENA (ethylene-bridged nucleic acid), PNA (peptide nucleic acid), and tcDNA (tricyclic DNA).
[0151] In some embodiments, the oligonucleotide hybridizes to at least a portion of the AttD site in the CSSDNA. In some embodiments, the LNA is located on an oligonucleotide at a distance of at least 5, 10, 15, 20, or 25 nucleotides from the dinucleotide core of the AttD site.
[0152] III. Nucleic Acid Modification
[0153] In some embodiments, the mRNA and / or CSSDNA in the genome editing system are modified. This encompasses any DNA or mRNA modification known to those skilled in the art. In some embodiments, the modified mRNA or DNA is synthesized using non-canonical nucleosides or nucleotides. Modifications (such as those listed herein) can be combined to provide modified mRNA or DNA containing two, three, four, or more modified nucleosides and nucleotides. In some embodiments, each base of the mRNA or DNA is modified, for example, all bases have a modified phosphate group, such as a thiophosphate group. In some embodiments, the modified mRNA or DNA contains at or near the 5' end and / or the 3' end of the RNA or DNA.
[0154] In some embodiments, the mRNA or DNA contains one, two, three, or more modified nucleosides or nucleotides. In some embodiments, at least 5% (e.g., at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100%) of the modified mRNA or DNA is a modified nucleoside or nucleotide.
[0155] In some embodiments, the mRNA modification includes uridine modification. In some embodiments, the mRNA modification includes 1-methyl-pseudouridine. In some embodiments, the mRNA modification includes pseudouridine. In some embodiments, the mRNA modification includes replacing each uridine with 1-methyl-pseudouridine. In some embodiments, the mRNA modification includes replacing each uridine with pseudouridine.
[0156] Some embodiments encompass modification of the phosphate ester backbone. Examples of modified phosphate ester groups include thiophosphates, selenophosphates, borano phosphates, borano phosphate esters, hydrophosphonates, aminophosphates, alkyl or aryl phosphonates, and phosphate triesters. The backbone can also be modified by replacing bridging oxygens with nitrogen (bridged aminophosphate), sulfur (bridged thiophosphate), and carbon (bridged methylene phosphonate). The substitution can occur at any one of the linked oxygens or at both linked oxygens. In some embodiments, the phosphate ester groups can be replaced by phosphorus-free linkers. In some embodiments, charged phosphate ester groups can be replaced by neutral portions. Examples of phosphate ester group substitutes include, but are not limited to, methylphosphonates, hydroxyamino groups, siloxanes, carbonates, carboxymethyl groups, carbamates, amides, thioethers, ethylene oxide linkers, sulfonates, sulfonamides, thioformacetals, formacetals, oximes, methyleneimino, methylenemethylimino, methylenehydrazine, methylenedimethylhydrazine, and methyleneoxymethylimino. In some embodiments, the phosphate ester linker and ribose are replaced by nuclease-resistant nucleosides or nucleotide substitutes. Examples include, but are not limited to, morpholino, cyclobutyl, pyrrolidine, and peptide nucleic acid (PNA) nucleoside substitutes.
[0157] Some embodiments encompass sugar modification. For example, a 2' hydroxyl group (OH) can be modified. In some embodiments, the 2' hydroxyl group modification can be 2'-O-Me. In some embodiments, the 2' hydroxyl group modification can be a 2'-fluorinated modification. In some embodiments, the 2' hydroxyl group modification can include a "locked" nucleic acid (LNA). In some embodiments, the 2' hydroxyl group modification can include an "unlocked" nucleic acid (UNA) where the ribose ring lacks a C2'-C3' bond. In some embodiments, the 2' hydroxyl group modification can include a methoxyethyl group. The “deoxy” 2' modification is encompassed and may include hydrogen, a halogen (e.g., bromine, chlorine, fluorine, or iodine), an amino group (e.g., NH2; alkylamino, dialkylamino, heterocyclic, arylamino, diarylamino, heteroarylamino, diheteroarylamino, or amino acid), NH(CH2CH2NH)nCH2CH2-amino, -NHC(O)R (where R may be, for example, alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, or sugar), cyano, mercapto, alkyl-thio-alkyl, thioalkoxy, and alkyl, cycloalkyl, aryl, alkenyl, and alkynyl groups that may optionally be substituted with, for example, an amino group. In some embodiments, the modified nucleic acid comprises arabinose. In some embodiments, the modified nucleic acid comprises abasic sugar. In some embodiments, the modified nucleic acid comprises one or more sugars in the L-form.
[0158] IV. Methods
[0159] In some aspects, methods for generating engineered cells are provided, including contacting the cells with any of the compositions disclosed herein or a genome editing system. In some embodiments, methods for introducing a sequence of interest into cells are provided, including contacting the cells with any of the compositions disclosed herein or a genome editing system. In some embodiments, methods for treating a disease in a subject are disclosed, including administering to the subject any of the compositions disclosed herein, a genome editing system, or engineered cells. In some embodiments, the method occurs in vivo. In some embodiments, the method occurs in vitro. In some embodiments, the method occurs ex vivo. In some embodiments, the sequence of interest is a CAR. In some embodiments, the cells are T cells.
[0160] In some aspects, this disclosure provides a method for integrating a sequence of interest into a cellular genome, the method comprising contacting a cell with any one or more of the disclosed compositions or a genome editing system such that the sequence of interest is integrated into the cellular genome. In some embodiments, the method occurs in vivo. In some embodiments, the method occurs in vitro. In some embodiments, the method occurs ex vivo.
[0161] In some embodiments, methods for editing chromosomal locations in human cells include contacting the human cell with any one or more of the disclosed compositions or genome editing systems, such that the recombination activity of the LSR results in the integration of the sequence of interest from the composition or genome editing system into the cell's genome. The location of integration is determined by the presence of one or more AttA sites in the genome, where the AttA sites, together with AttD sites, form homologous attachment sites. In some embodiments, integration occurs at sites that do depend on an endogenous promoter for expression of the sequence of interest. In some embodiments, integration occurs at sites where an endogenous promoter can be used to express the sequence of interest.
[0162] In some aspects, this disclosure provides a method for integrating a sequence of interest into a GS10 integration site in an immune cell using a composition or genome editing system, such that a protein encoded by the sequence of interest is expressed by the cell. The GS10 integration site is chr10:69637352-69637354 (Hg38 genome). In some embodiments, the immune cell is a T cell. In other embodiments, the immune cell is a B cell, NK cell, lymphocyte, or bone marrow cell. In some embodiments, the protein encoded by the sequence of interest is a therapeutic protein. In some embodiments, the protein encoded by the sequence of interest is an antigen receptor, such as a CAR. In some embodiments, the composition or genome editing system includes (a) mRNA encoding an LSR and (b) cssDNA containing AttD and the sequence of interest (e.g., encoding a therapeutic protein, antigen receptor, or CAR). In some embodiments, the composition or genome editing system further includes a lipid-based formulation comprising (a) and (b). In some embodiments, the lipid-based formulation contains an LNP. In some embodiments, the LSR has at least 90%, 95%, 99%, or 100% identity with the amino acid sequence of SEQ ID NO: 2024, 2029, or 2030. In some embodiments, the cssDNA comprises SEQ ID NO: 2025. In some embodiments, the ratio of b) to a) in the LNP is 3:1 to 1:3. In some embodiments, the ratio of b) to a) in the LNP is 2:1 to 1:2. In some embodiments, the ratio of b) to a) in the LNP is 1:1.
[0163] In some embodiments, the composition or gene editing system exhibits lower immunogenicity after introduction into cells compared to double-stranded DNA or plasmid controls. For example, in some embodiments, the gene editing system, upon integration into primary T cells, exhibits reduced levels of phosphorylated proteins pTBK1, pTIRF3, and / or pSTING compared to a double-stranded DNA control. In some embodiments, the gene editing system results in reduced levels of IL6, IFNa, IFNb, and / or TNFα in vivo compared to a double-stranded DNA control.
[0164] In some embodiments, the methods disclosed herein lead to the generation of CAR-T cells. In some embodiments, Cas or guide RNA is not used in cell contact.
[0165] This disclosure provides a method for treating a subject with a disease using the compositions or genome editing systems disclosed herein. In some embodiments, the disease is cancer. In some embodiments, the disease is caused by a gene mutation. Non-limiting examples of mutations include polymorphisms such as single nucleotide polymorphisms (SNPs), point mutations, frameshift mutations, genomic rearrangements, translocations, and inversions. In some embodiments, the disease is caused by a polymorphism. In some embodiments, the disease is caused by an SNP.
[0166] In some embodiments, the method includes administering an effective amount of a composition or genome editing system to a subject, wherein the sequence of interest of the composition or genome editing system is integrated into the subject's genome, thereby treating the subject's disease.
[0167] In some embodiments, methods are provided for contacting a subject with a composition or genome editing system comprising (a) mRNA encoding an LSR, and (b) cssDNA containing an AttD and a sequence of interest, wherein (a) and (b) are included in a lipid-based formulation containing an LNP, wherein the sequence of interest encodes a CAR, thereby generating CAR+ cells in the subject. In some embodiments, the cells are immune cells, such as T cells. In some embodiments, cssDNA has reduced immunogenicity in the subject compared to dsDNA, such that the level of CAR+ cells is sufficient to treat the subject's cancer. In some embodiments, the reduced immunogenicity can be manifested by lower levels of inflammatory cytokines (such as IL6, IFN-α, IFN-β, or MCP-1) in the subject compared to a subject who has been administered a composition or genome editing system containing dsDNA encoding the sequence of interest. In some embodiments, reduced immunogenicity can be demonstrated by no significant change in the subject's body weight and / or no significant increase in one or more inflammatory cytokines (such as IL6, IFN-α, IFN-β, or MCP-1) after administration of the composition or system. In some embodiments, the cells are T cells, and the level of CAR-T cells in the subject is sufficient to deplete the subject's B cells. In some embodiments, the cells are T cells, and the level of CAR-T cells is sufficient to reduce the tumor burden in the subject. In some embodiments, the LSR has at least 90%, 95%, 99%, or 100% identity with the amino acid sequence of SEQ ID NO: 2024, 2029, or 2030. In some embodiments, the cssDNA comprises SEQ ID NO: 2025. In some embodiments, the ratio of b) to a) in the LNP is 3:1 to 1:3. In some embodiments, the ratio of b) to a) is 2:1 to 1:2. In some embodiments, the ratio of b) to a) in the LNP is 1:1.
[0168] In some aspects, this disclosure provides methods for treating a subject's disease by administering any one or more of the disclosed compositions or genome editing systems to a patient in need, thereby generating engineered cells in the patient's body. In some aspects, this disclosure provides methods for treating a subject's disease by generating engineered cells using any one or more of the disclosed compositions or genome editing systems and administering the engineered cells to the subject, thereby treating the disease. In some embodiments, the method of treating a subject's disease includes (i) contacting isolated cells with an effective amount of any one or more of the disclosed compositions or genome editing systems to generate engineered cells, and (ii) administering the engineered cells to the subject, thereby treating the disease. In some embodiments, the subject is a human being. In some embodiments, the disease is caused by a gene mutation.
[0169] Any suitable cell type may be used in the embodiments disclosed herein. In some embodiments, the cell or genome is a T cell, natural killer cell, induced pluripotent stem cell, hematopoietic stem cell, hepatocyte, myocyte, B cell, fibroblast, neuron, astrocyte, or microglia.
[0170] In some embodiments, the cell is a T cell. In some embodiments, the cell is a natural killer cell. In some embodiments, the cell is an induced pluripotent stem cell. In some embodiments, the cell is a hematopoietic stem cell. In some embodiments, the cell is a hepatocyte. In some embodiments, the cell is a myocyte. In some embodiments, the cell is a B cell. In some embodiments, the cell is a fibroblast. In some embodiments, the cell is a neuron. In some embodiments, the cell is an astrocyte. In some embodiments, the cell is a microglia.
[0171] The number of treatments administered to a subject can vary. Introducing engineered cells into a subject can be a one-time event; however, in some cases, this treatment may induce improvement over a limited period and require a series of repeated treatments. In other cases, multiple administrations of engineered cells may be necessary before an effect is observed. The precise protocol depends on the disease or symptom, the stage of the disease, and the parameters of the individual subject being treated.
[0172] This disclosure provides a composition or genome editing system for use in treating a subject with a disease, wherein said use includes administering an effective amount of the composition or genome editing system to the subject or contacting isolated cells with an effective amount of the composition or genome editing system to generate engineered cells and administering the engineered cells to the subject. In some embodiments, the disease is cancer. In some embodiments, the disease is caused by a gene mutation. In some embodiments, the use includes administering an effective amount of the composition or genome editing system to the subject. In some embodiments, the use includes contacting isolated cells with an effective amount of the composition or genome editing system to generate engineered cells and administering the engineered cells to the subject.
[0173] In some embodiments, the engineered cells disclosed herein are CAR-T cells. In some embodiments, the level of CAR-T cells administered to the subject is sufficient to deplete the subject's B cells. In some embodiments, the level of CAR-T cells is sufficient to reduce the subject's tumor burden.
[0174] This disclosure provides the use of the composition or genome editing system in the manufacture of a pharmaceutical. In some embodiments, the pharmaceutical is used to treat diseases caused by gene mutations. In some embodiments, the pharmaceutical is used to treat cancer.
[0175] V. Pharmaceutical Composition
[0176] The compositions and genome editing systems disclosed herein can be formulated into pharmaceutical compositions by combination with suitable pharmaceutically acceptable carriers, diluents, or mediators. Pharmaceutically acceptable mediators can be those approved by federal or state regulatory agencies or listed in the United States Pharmacopeia or other recognized pharmacopoeias for use in mammals (such as humans). In some embodiments, the disclosed genome editing system is administered to a subject via intravenous, parenteral, intraperitoneal, intradermal, transdermal, intratracheal, or intraocular administration. The active agent can be systemic after administration or localized via regional or targeted delivery mechanisms.
[0177] General considerations
[0178] Throughout this disclosure, substituents or properties of the compounds are disclosed in groups or ranges. This disclosure is intended to include individual members and each sub-combination of such groups and ranges, and such groups or ranges include endpoints. As a non-limiting example, if a group or range is from about 1 to about 10, then the group or range includes both values of about 1 and about 10.
[0179] Articles such as “a,” “an,” and “the / described” may indicate one / an or more than one / an unless otherwise indicated or obvious from the context. A claim, embodiment, or description including “or” among one or more members of the group is considered satisfied if one, more than one, or all of the group members are present in, used in, or otherwise associated with a given product or process, are used in, or are otherwise associated with a given product or process, unless otherwise indicated or obvious from the context. This disclosure may include embodiments in which exactly one member of the group is present in, used in, or otherwise associated with a given product or process. This disclosure may also include embodiments in which more than one or all of the group members are present in, used in, or otherwise associated with a given product or process.
[0180] The term “comprising” is intended to be open-ended and allows, but does not require, the inclusion of additional elements or steps. When the term “comprising” is used herein, the terms “consisting of” and “substantially consisting of” are also covered and disclosed.
[0181] The abbreviation “for example (eg,)” comes from the Latin word for example (exempli gratia) and is used herein to indicate a non-restrictive instance. Therefore, the abbreviation “for example” is synonymous with the term “for instance.” The abbreviation “that is (ie,)” comes from the Latin word that is (id est) and is used herein to indicate a non-restrictive restatement or clarification. Therefore, the abbreviation “that is” is synonymous with the term “that is.”
[0182] Any embodiment of this disclosure that falls within the prior art may be expressly excluded from any one or more claims. Any embodiment of the pharmaceutical, method, and / or composition of this disclosure may be excluded from any one or more claims for any reason, whether or not related to the existence of prior art.
[0183] In the event of any publications, patent applications, patents and other references mentioned herein being incorporated by way of citation and conflicting with this specification, this specification shall prevail.
[0184] The chapter titles, materials, methods, and examples are illustrative only and are not intended to be limiting.
[0185] Example
[0186] Example 1: Preparation of Circular Single-Stranded DNA
[0187] Circular single-stranded DNA constructs were prepared for evaluation compared to double-stranded DNA plasmids. Two cssDNA constructs were prepared for use with the Cp36 LSR: 1) “cssDNA5” (SEQ ID NO: 4000) encodes the AttD site (SEQ ID NO: 2001) corresponding to 5' to 3' Cp36, EF1α, mCherry, bGHpA, f1 origin of replication, ColE1, and AmpR; 2) “cssDNA6” (SEQ ID NO: 4001) encodes the AttD site (SEQ ID NO: 2001) corresponding to 5' to 3' Cp36, EF1α, mCherry, bGHpA, and f1 origin of replication. See also Figure 1A .
[0188] For experiments using Bxb1, the following cssDNA construct "cssDNA8" (SEQ ID NO: 4002) was prepared, encoding the AttD site (SEQ ID NO: 2003) corresponding to 5' to 3' - Bxb1, mCherry, bGHpA, and f1 origin of replication. See also Figure 6A .
[0189] The CSSDNA construct was prepared as follows: Phage plasmids encoding CSSDNA5, CSSDNA6, or CSSDNA8, along with helper plasmids, were co-transformed into *E. coli* XL1-Blue competent cells. Cells were plated on LB agar plates containing 100 µg / mL carbenicillin and 50 µg / mL kanamycin and grown overnight at 37°C. Single colonies were inoculated into 3 mL of 2xYT medium containing carbenicillin, kanamycin, and MgSO4 in 14 mL Falcon round-bottom tubes and grown overnight in a New Brunswick Innova 44 shaking incubator at 37°C and 220 rpm. 0.5 mL of the grown cell culture was transferred to 250 mL of 2xYT medium containing carbenicillin, kanamycin, and MgSO4 in a 1000 mL Erlenmeyer flask and grown overnight in a shaking incubator at 37°C and 220 rpm. Transfer the culture to a 250 mL PPCO centrifuge bottle and centrifuge at 6,000 g and 4 °C for 30 min in a Sorvall LYNX 4000 ultracentrifuge. Collect the supernatant containing the phage in a 500 mL Pyrex medium storage bottle and discard the E. coli cell precipitate. To purify the phage, add 72 mL of 50% (w / v) PEG8000 and 36 mL of 5M NaCl to the phage solution. Incubate the phage-PEG / NaCl mixture at 4 °C for 24 h, then centrifuge at 15,000 g for 30 min. After discarding the supernatant, centrifuge the mixture at 15,000 g for 10 min. Gently remove the supernatant and redisperse the phage-PEG / NaCl precipitate in 20 mL of 1x TBS buffer using vortexing. The redispersed phage solution was centrifuged at 15,000 g and 4°C for 20 min, and the supernatant was transferred to a new tube. To remove any extra DNA or RNA from the phage solution, MgCl2, DNase I, and RNase A were added to the solution. The solution was incubated in a shaking incubator at 37°C and 220 rpm for 2 h. To inactivate DNase I, the solution was incubated at 70°C for 10 min. To lyse the phage particles and extract cssDNA, 20 mL of M2 buffer (2% Triton X-100, 1 M guanidine-HCl, 20 mM MOPS, pH 6.5) was added, and the solution was incubated at 80°C for 1 h. The solution was cooled to room temperature and centrifuged at 15,000 g for 10 min. The supernatant was transferred to a new 50 mL endotoxin-free centrifuge tube. To remove endotoxin from the solution, 2.5 mL of Qiagen buffer ER was added, and the solution was incubated on ice for 30 min.The cssDNA was then purified using Qiagen-tip 500, Buffer QC, and Buffer QN from the Qiagen Endofree Plasmid Maxi Kit. The purified cssDNA was further purified using the Norgen Biotek Endotoxin Removal Kit (Mini) to reduce endotoxin levels. The concentration of cssDNA was measured using Nanodrop, and the endotoxin level was measured using Endosafe nexgen-PTS.
[0190] The purified CSSDNA constructs at the expected size were shown on the CSSDNA agarose gel electrophoresis results. Figure 1B (for Cp36) and Figure 6B (For BxB1).
[0191] Example 2: Reduced immunogenicity with the use of cssDNA
[0192] The immunogenicity of cssDNA was compared with that of dsDNA in THP1-Dual™ cells (thpd-nfis, InvivoGen). The cssDNA construct from Example 1 was used. The dsDNA construct was a nanoparticle (SEQ ID NO: 4003) encoding from 5' to 3': Bxb1AttA, Pa01AttD, Si74AttD, and Cp36AttD, ApoE, hAAT, hEPO, 2A, and Firefly. The nanoparticle was synthesized by Genscript (<0.01 EU / µg).
[0193] Endotoxin levels in cssDNA were reduced using the Norgen Biotek Endotoxin Removal Kit. Following the removal process, the endotoxin levels for cssDNA5 and cssDNA6 were 0.049 EU / µg and 0.042 EU / µg, respectively. The endotoxin level for cssDNA8 was 0.016 EU / µg.
[0194] THP1-Dual™ cells were seeded at 50,000 cells / well in 100 µL of medium in 96-well round-bottom plates consisting of RPMI 1640 (Gibco), 9% FBS (Gibco), and 1x Pen-Strep (Gibco). After one hour, 2 µg of cssDNA or dsDNA was added to 100 µL of LyoVec (lyec-1, InvivoGen) and briefly mixed with a pipette. The solution was incubated at room temperature for 15 minutes and then fed to the cells. After overnight incubation, 20 µL of supernatant from each well was pipetted into a new white 96-well plate. Luciferase dye (rep-qlc4lg1, InvivoGen) was diluted 1:20 with water, and 50 µL of the diluted luciferase solution was added to each well. The mixture was immediately measured using a luminometer (SpectraMax i3x) with a readout time of 0.1 seconds. The measurement results were plotted as luminescence multiples relative to the background, where the background refers to untreated cell conditions.
[0195] Figure 2A and 2B The results show the fold increase in luciferase relative to background with increasing doses of cssDNA5 and cssDNA6, and the immunogenicity of cssDNA is lower than that of dsDNA.
[0196] Example 3: Integration of cssDNA into HEK293FT cells with LSR Cp36
[0197] Genomic integration of CSSDNA was evaluated in HEK293FT cells at specific dose ranges using the CSSDNA construct from Example 1. The CSSDNA construct was a CSSDNA plasmid (“pAF999”; SEQ ID NO: 4004) encoding, from 5' to 3': the AttD site corresponding to Cp36 (SEQ ID NO: 2001), EF1α, PuroR, 2A, mCherry, bGHpA, pUC, and AmpR. The LSR used for testing was 1xFlag-Cp36 (1xFlag-Cp36 mRNA (SEQ ID NO: 2000)). See Durrant et al., Nature Biotechnology 41, 488-499 (2023); WO2023081762. The mRNA encoding 1xFlag-Cp36 was purchased from TriLink Technologies.
[0198] On day 1, 1xFlag-Cp36 mRNA and DNA (cssDNA or dsDNA) were delivered to HEK293FT cells via reverse transfection in 96-well plates. Following the manufacturer's protocol, 100 ng mRNA / well was prepared using Lipofectamine Messenger MAX, and different doses of DNA (cssDNA or dsDNA) were prepared using Lipofectamine 3000. The mRNA and DNA mixtures were then added to each well. 30,000 cells (Figure 3) or 60,000 cells (Figure 4) were seeded per well of the 96-well plate. Figure 4 Cells were incubated for 48 hours, and total DNA was extracted using the Quick-DNA 96 kit (Zymo Research, D3010) for ddPCR.
[0199] Integration percentage was measured by ddPCR. ddPCR was performed using the QX600 AutoDG Droplet Digital PCR System (Bio-Rad) according to the manufacturer's protocol. Each test sample was prepared in a 22 µL mixture comprising 5.5 µL of 4x ddPCR™ Supermix (dUTP-free) (Bio-Rad) for probes, forward / reverse primers (900 nM), FAM or HEX-labeled PrimeTime™ qPCR probes (250 nM), 4 units of HindIII-HF restriction enzyme (NEB), and 2.2 µL of DNA template (20–50 ng). This mixture was used to generate droplets using an automated droplet generator. The generated droplets were amplified using a PTC Tempo Deepwell thermal cycler, with initial denaturation at 95 °C for 10 min, followed by 40 cycles of denaturation at 94 °C for 30 s and annealing-extension at 60 °C for 60 s. Enzyme inactivation was performed at 98 °C for 10 min, followed by indefinite incubation at 4 °C. After amplification, droplets were quantified using a QX600 droplet reader (Bio-Rad). Data analysis was performed using QX Manager. Integration rate was defined as the concentration of the integrated target divided by the concentration of the reference gene. For the highest integration site, tests were performed using both the target and reference primers / probes, in duplicate. gBlocks were also generated to test the sensitivity of primer / probe design.
[0200] Primers and probes were designed using PrimerQuest (IDT) with default settings and ordered from IDT. The same primers and probes were used for both dsDNA and ssDNA templates when evaluating integration on the left side, but different forward primers were used for integration on the right side. gBlocks gene fragments (dsDNA from IDT) were ordered for each expected template sequence to validate primer / probe design and measure assay sensitivity. Primer and probe sequences are shown in Table 1 below.
[0201] Table 1: ddPCR reagents for Cp36
[0202]
[0203] The results of the integration percentage with Cp36 are shown in Figure 3A The integration rates of cssDNA and dsDNA at three doses (100 ng, 500 ng, and 1000 ng) were calculated and displayed. Figure 3B Among them, cssDNA achieves an integration rate of approximately 60%-70% with dsDNA.
[0204] In a separate experiment using Cp36, escalating doses of cssDNA were evaluated. As described above, 1xFlag-Cp36 mRNA and DNA (cssDNA or dsDNA) were delivered to cells on day 1 via reverse transfection with Lipofectamine. Forty-eight hours later, total DNA was extracted, and the integration rates on the left and right sides were assessed by ddPCR. The results for the percentage of integration with cssDNA on the left and right sides are shown in [the figures are missing from the original text]. Figure 4 middle.
[0205] Example 4: Integration of cssDNA into primary T cells via electroporation using LSR Cp36
[0206] Using the cssDNA6 construct from Example 1, genomic integration of cssDNA was evaluated in primary T cells within a defined cssDNA dosage range. The dsDNA construct was a dsDNA plasmid (“pAF999”; SEQ ID NO: 4004) encoding, from 5' to 3', the AttD site corresponding to Cp36 (SEQ ID NO: 2001), EF1α, PuroR, 2A, mCherry, bGHpA, pUC, and AmpR. The LSR used for testing was 1xFlag-Cp36 (1xFlag-Cp36 mRNA (SEQ ID NO: 2000)). The mRNA encoding 1xFlag-Cp36 was purchased from Trilink Technologies.
[0207] Two hundred million frozen primary human T cells were thawed and seeded every 2–3 days in 20 mL of X-Vivo-15 (Lonza BP04-774Q) medium in T75 tissue culture flasks. This medium consisted of 2% human serum (Valley Biomedical), CD3 / CD28 Dynabeads (Gibco, 11132D) with a bead-to-cell ratio of 3:1, and supplemented with 100 IU / mL IL-2 (STEMCELL Technologies). After 48–72 hours of activation, the T cells were harvested and counted.
[0208] The harvested cells were concentrated by centrifugation at 500 g for 5 minutes. The cell supernatant was removed, and the cells were resuspended in P3 primary cell solution (Lonza, V4XP-3032) supplemented with supplement 1 (Lonza, V4XP-3032). Each well of the 12-well nucleocuvette strip (Lonza, V4XP-3032) was loaded with 19 µL of P3 solution containing 200,000 cells and 1 µL of solution containing DNA and / or RNA, as shown below. Figure 5 As shown. The cuvette was placed in a 4D-Nucleofector (Lonza, AAF-1003X) and the cells were transfected with the EO-115 program.
[0209] Immediately after electroporation, cells were seeded at 50,000 cells / well in 96-well round-bottom plates (Corning, 351177) and diluted to 150 µL in culture medium. After activation for 48–72 hours, cells were harvested for ddPCR.
[0210] ddPCR was performed using the QX600 AutoDG Droplet Digital PCR System (Bio-Rad) according to the manufacturer's protocol. Each test sample was prepared in a 22 µL mixture comprising 5.5 µL of 4x ddPCR™ Supermix (dUTP-free) (Bio-Rad) for probes, forward / reverse primers (900 nM), FAM or HEX-labeled PrimeTime™ qPCR probes (250 nM), 4 units of HindIII-HF restriction enzyme (NEB), and 2.2 µL of DNA template (20–50 ng). This mixture was used to generate droplets using an automated droplet generator. The generated droplets were amplified using a PTC Tempo Deepwell thermal cycler, with initial denaturation at 95 °C for 10 min, followed by 40 cycles of denaturation at 94 °C for 30 s and annealing-extension at 60 °C for 60 s. Enzyme inactivation was performed at 98 °C for 10 min, followed by indefinite incubation at 4 °C. After amplification, droplets were quantified using a QX600 droplet reader (Bio-Rad). Data analysis was performed using QX Manager. Integration rate was defined as the concentration of the integrated target divided by the concentration of the RPPH reference gene. For each integration site, tests were performed using both the target and reference primers / probes, in duplicate. gBlocks were also generated to test the sensitivity of the primer / probe design.
[0211] The results of the integration percentage with Cp36 are shown in Figure 5 middle.
[0212] Example 5: Integration of cssDNA into HEK293FT cells expressing LSR BxB1
[0213] Genomic integration of cssDNA was evaluated in HEK293FT cells at dose ranges using Lipofectamine, Messenger Max, or LNP, and the cssDNA8 construct from Example 1. The dsDNA construct was a dsDNA plasmid (“pAF755”; SEQ ID NO: 4005) encoding from 5' to 3': the AttD site corresponding to Bxb1 (SEQ ID NO: 2003), mCherry, bGHpA, pUC, and AmpR. The LSR used for testing was Bxb1 (SEQ ID NO: 2002). Bxb1 was expressed in Bxb1 landing pad HEK293FT cells prepared using lentiviral transduction as follows. Lentiviral cells were generated by transfecting HEK293T cells with a packaging plasmid encoding the proteins required for the assembly of mature virions, a pseudotyped plasmid encoding the vesicular stomatitis virus G protein (VSV-G), and a transfer plasmid (“pJT301”, SEQ ID NO:4006) containing modified 5' and 3' long terminal repeats (LTRs) and an expression cassette containing the EF1α promoter, the Bxb1 AttA receptor site, and an open reading frame encoding the Bxb1 enzyme, the P2A peptide, and the EGFP reporter gene. The region of the 5' to 3' LTR in the transfer plasmid pJT301 (i.e., the “Bxb1 landing pad”) was integrated into the cellular genome of HEK293FT cells to generate Bxb1 landing pad cells.
[0214] On day 1, DNA (cssDNA or dsDNA) was delivered to HEK293FT cells via reverse transfection in 96-well plates. Lipofectamine 3000 (…) Figure 7A ) or Lipofectamine MessengerMAX ( Figure 7B Different doses of DNA (cssDNA or dsDNA) were prepared, and the DNA mixture was then added to each well. 60,000 cells were seeded in one well of a 96-well plate. After incubation for 48 hours, cells were harvested, and total DNA was extracted using the Quick-DNA 96 kit (Zymo Research, D3010) for ddPCR.
[0215] Integration percentage was measured by ddPCR. ddPCR was performed using the QX600 AutoDG Droplet Digital PCR System (Bio-Rad) according to the manufacturer's protocol. Each test sample was prepared in a 22 µL mixture comprising 5.5 µL of 4x ddPCR™ Supermix (dUTP-free) (Bio-Rad) for probes, forward / reverse primers (900 nM), FAM or HEX-labeled PrimeTime™ qPCR probes (250 nM), 4 units of HindIII-HF restriction enzyme (NEB), and 2.2 µL of DNA template (20–50 ng). This mixture was used to generate droplets using an automated droplet generator. The generated droplets were amplified using a PTC Tempo Deepwell thermal cycler, with initial denaturation at 95 °C for 10 min, followed by 40 cycles of denaturation at 94 °C for 30 s and annealing-extension at 60 °C for 60 s. Enzyme inactivation was performed at 98 °C for 10 min, followed by indefinite incubation at 4 °C. After amplification, droplets were quantified using a QX600 droplet reader (Bio-Rad). Data analysis was performed using QX Manager. Integration rate was defined as the concentration of the integrated target divided by the concentration of the reference gene. For the highest integration site, tests were performed using both the target and reference primers / probes, in duplicate. gBlocks were also generated to test the sensitivity of primer / probe design.
[0216] Primers and probes were designed using PrimerQuest (IDT) with default settings and ordered from IDT. The same primers and probes were used for both dsDNA and ssDNA templates when evaluating integration on the left side, but different forward primers were used for integration on the right side. To calculate the integration percentage, the integrated DNA was compared to the number of available landing pad sites measured by orthogonal sets of primers and probes. gBlocks gene fragments (dsDNA from IDT) for each expected template sequence were ordered to validate primer / probe design and measure assay sensitivity. Primer and probe sequences are shown in Table 2 below.
[0217] Table 2: ddPCR reagents for Bxb1
[0218]
[0219] Results of the integration percentages for the left and right sides using Lipofectamine 3000 transfection and Lipofectamine MessengerMAX with Bxb1 are shown below. Figure 7A and 7B middle.
[0220] The lipid nanoparticle (LNP) formulation was prepared as follows. Five lipids (ionizable lipid, cofactor lipid (DSPC (BP-25623)), cholesterol (BP-26125), β-sitosterol (BP-40650), and PEG lipid (DMG-PEG 2000 (BP-25496), all purchased from Broadpharm) were dissolved in ethanol at a ratio of 50:23:10:15:2. The lipid mixture was combined with an acidic aqueous buffer containing DNA at a volume ratio of 3:1 (aqueous solution: ethanol) using a microfluidic mixer (Ignite, Percision Nanosystems). The formulation was dialyzed in a dialysis chamber against 50 mM Tris (pH 7.5), 75 mM sodium chloride, and 10% sucrose for at least 18 hours. The formulation was stored at -80°C until further use.
[0221] Different doses of LNP-DNA (cssDNA or dsDNA) were added to 96-well plates supplemented with ApoE (final concentration 3 ng / µl), and then Bxb1-LP HEK 293FT cells were added to the 96-well plates at a density of 60,000 cells / well. After incubation for 48 hours, cells were harvested, and total DNA was extracted for ddPCR using the Quick-DNA 96 Kit (Zymo Research, D3010). Results showing the percentage of LNP integration for the left and right sides in the case of Bxb1 are shown in the figure. Figure 8 middle.
[0222] Example 6: Integration of CSSDNA with single-stranded DNA-binding proteins
[0223] Genomic integration of cssDNA was evaluated in HEK293FT cells with the addition of the single-stranded DNA-binding protein RAD51. The construct cssDNA6 (Example 1) and the LSR 1xFlag-Cp36 plasmid were used in the experiments. The cssDNA6 and 1xFlag-Cp36 plasmids were compared with the cssDNA6 and 1xFlag-Cp36-2A-RAD51 plasmid. The LSR 1xFlag-Cp36 and RAD51 proteins were expressed using the EF1α promoter in the plasmids. The sequence of RAD51 is provided as SEQ ID NO: 4007.
[0224] On day 1, cssDNA and LSR DNA were delivered to HEK293FT cells in 96-well plates via electroporation. Electroporation was performed using 250 ng 1xFlag-Cp36 or 1xFlag-Cp36-2A-RAD51 plasmid / well, 1000 ng cssDNA6 / well, or 250 ng pAF999 / well, according to the manufacturer's protocol. Electroporation was performed using a 4D-Nucleofector (Lonza, AAF-1003X) with the DS-150 protocol.
[0225] ddPCR was performed using the QX600 AutoDG Droplet Digital PCR System (Bio-Rad) according to the manufacturer's protocol. Each test sample was prepared in a 22 µL mixture comprising 5.5 µL of 4x ddPCR™ Supermix (dUTP-free) (Bio-Rad) for probes, forward / reverse primers (900 nM), FAM or HEX-labeled PrimeTime™ qPCR probes (250 nM), 4 units of HindIII-HF restriction enzyme (NEB), and 2.2 µL of DNA template (20–50 ng). This mixture was used to generate droplets using an automated droplet generator. The generated droplets were amplified using a PTC Tempo Deepwell thermal cycler, with initial denaturation at 95 °C for 10 min, followed by 40 cycles of denaturation at 94 °C for 30 s and annealing-extension at 60 °C for 60 s. Enzyme inactivation was performed at 98 °C for 10 min, followed by indefinite incubation at 4 °C. After amplification, droplets were quantified using a QX600 droplet reader (Bio-Rad). Data analysis was performed using QX Manager. Integration rate was defined as the concentration of the integrated target divided by the concentration of the RPPH reference gene. For each integration site, tests were performed using both the target and reference primers / probes, in duplicate. gBlocks were also generated to test the sensitivity of the primer / probe design.
[0226] ddPCR primers and probes (SEQ ID NO: 2004, 2005, 2006). The integration percentage determined by ddPCR is shown in... Figure 9 middle.
[0227] Example 7: cssDNA reduces cGAS pathway-related immunogenicity in human primary T cells and in vivo.
[0228] The immunogenicity characteristics of the cssDNA construct were evaluated in human primary T cells. The construct cssDNA6 was prepared as in Example 1 (Example 1).
[0229] Human peripheral blood pan-T cells (StemCells) were stimulated in X-Vivo 15 medium (Lonza) supplemented with 2% human AB serum (Valley Biomedical) using Dynabead human T activator CD3 / CD28 (ThermoFisher) at a ratio of 75 μL Dynabeads / 1e6 T cells, along with 100 IU / mL IL-2, 10 ng / mL IL-7, and 10 ng / mL IL-15 (StemCell). After 3 days, Dynabeads were magnetically removed, and T cells were electroporated in P3 buffer using the EO-115 procedure on a 4D-Nucleofector X unit (Lonza). Electroporation was performed using 2e6 activated T cells and (i) no additives, (ii) 4 μg cGAMP / 1e6 cells, (iii) 4 μg circular single-stranded DNA (cssDNA6) / 1e6 cells, or (iv) 4 μg nanoparticle double-stranded DNA / 1e6 cells. One hour after electroporation, cells were harvested and lysed using RIPA buffer (ThermoFisher) supplemented with HALT protease and phosphatase inhibitors. Protein lysates were quantified using the Pierce BCA Protein Assay Kit (ThermoFisher), and 20 μg of protein from each lysate was loaded onto a Western blot. The blot membrane was then stained against GAPDH and phosphorylated proteins pTBK1, pIRF3, and pSTING (all antibodies at 1:1000) (Cell Signaling Technology, Inc.).
[0230] Compared to cGAMP and nanoparticle DNA samples, cssDNA samples showed decreased levels of pTBK1, pTIRF3, and pSTING. Figure 11 ).
[0231] Immunogenicity was further evaluated in vivo in C57BL / 6j wild-type mice with LNP delivery of cssDNA6 (SEQ ID NO: 4001). Mice were injected via tail vein with 1 mg / kg LNP containing cssDNA or nanoparticles or plasmids (25 μg LNP for 25g mice). Four hours later, 100 µl of blood was collected retro-orbital, and the serum was processed for cytokine assays. A set of cytokine levels were tested using the LEGENDplex™ mouse antiviral response group (Biolegend, CAT# 740621). Body weight was recorded daily until 7 days after LNP injection.
[0232] Mice injected with cssDNA exhibited a reduced immune response, as demonstrated by decreased cytokine levels. Figures 19A-19D ), and there was no statistically significant change in weight. Figure 19E Compared to nanoparticles or plasmids, cssDNA exhibits IL-6 (…). Figure 19A ), IFN-a ( Figure 19B ), IFN-b ( Figure 19C ) and MCP-1 ( Figure 19D The decrease of ).
[0233] Example 8: Integration of cssDNA template into HEK293FT cells with LSR variant
[0234] Integration of cssDNA with an LSR variant (SEQ ID NO: 2024) (targeting the genome's LSR) was evaluated by transient transfection in HEK293FT cells. The following cssDNA construct, “cssDNA10” (SEQ ID NO: 4008), was prepared as in Example 1, encoding the AttD site (SEQ ID NO: 2025)-CMV-hEPO-2A-eGFP-bGHpA-f1 origin of replication corresponding to the LSR variant from 5' to 3'. The LSR variant construct was 3xMyc-NLS-Flag-LSR as mRNA.
[0235] One day prior to transfection, HEK293FT cells (Thermo Fisher Scientific) were seeded at 20,000 cells / mL in 96-well plates. Following the manufacturer's protocol, cssDNA was transfected using Lipofectamine 3000 (Thermo Fisher Scientific) at the specified dose, and following the manufacturer's protocol, 250 ng of 3xMyc-NLS-Flag-LSR mRNA was transfected per well using MessengerMAX (Thermo Fisher Scientific).
[0236] Two days post-transfection, genomic DNA was harvested using the Quick-DNA 96 kit (Zymo), and ddPCR was performed using the QX600AutoDG Droplet Digital PCR System (Bio-Rad) to quantify the integration event at the genomic integration site, designated "GS10". Each test sample was prepared using 2x ddPCR™ Supermix (dUTP-free) (Bio-Rad) for probes, forward / reverse primers (900 nM), FAM or HEX-labeled PrimeTime™ qPCR probes (250 nM), HindIII-HF restriction enzyme (NEB), and 20–50 ng of DNA template. Reaction mixture droplets were generated using an automated droplet generator, and DNA amplification was performed in the generated droplets using a PTC Empo DeepWell thermal cycler (Bio-Rad), followed by enzyme inactivation. The droplets were then quantified using a QX600 droplet reader (Bio-Rad). Data analysis was performed using QX Manager (Bio-Rad) to count positive and negative droplets for each probe and to calculate integration events relative to RPPH1, which serves as a genomic copy number reference. The primers for the GS10 site were SEQ ID NO: 2026 (forward primer), SEQ ID NO: 2027 (reverse primer), and SEQ ID NO: 2028 (probe FAM).
[0237] In the case of using variant LSR, the percentage of integration at the GS10 site increased with increasing cssDNA amount. Figure 12 ).
[0238] Example 9: cssDNA can be used as an LSR template to integrate CAR into human primary T cells.
[0239] The integration of CAR sequences using cssDNA as an LSR template in human primary T cells with an LSR variant (SEQ ID NO: 2024) was evaluated. The following cssDNA construct, “cssDNA19” (SEQ ID NO: 4010), was prepared as in Example 1, encoding the AttD site (SEQ ID NO: 2025)-EF1a-CAR-bGHpA-f1 origin of replication corresponding to the LSR variant from 5' to 3'. The LSR variant construct was 3xMyc-NLS-Flag-LSR as mRNA.
[0240] Human peripheral blood pan-T cells (StemCells) were stimulated in X-Vivo 15 medium (Lonza) supplemented with 2% human AB serum (Valley Biomedical) using Dynabead human T activator CD3 / CD28 (ThermoFisher) at a ratio of 75 μL Dynabeads / 1e6 T cells, along with 100 IU / mL IL-2, 10 ng / mL IL-7, and 10 ng / mL IL-15 (StemCell). One day later, Dynabeads were magnetically removed, and T cells were electroporated in P3 buffer using the EO-115 procedure on a 4D-Nucleofector X unit (Lonza). Electroporation consisted of 2e6 activated T cells and (i) 6 μg LSR mRNA / 1e6 cells, (ii) 2 μg CAR-encoding nanoparticle double-stranded DNA / 1e6 cells, (iii) 2 μg each of CAR-encoding cssDNA and 6 μg LSR mRNA / 1e6 cells, or (iv) 4 μg each of CAR-encoding cssDNA and 6 μg LSR mRNA / 1e6 cells. After electroporation, the cells were placed back onto CD3 / CD28 Dynabeads at the same ratio as before. Cytokines were supplemented every other day at the same concentration. Seven days after electroporation, the cells were harvested and divided into two populations for flow cytometry using a FITC-labeled monoclonal anti-FMC63 antibody (Acro Biosystems) and for genomic DNA analysis by ddPCR. Genomic DNA was harvested using the Quick-DNA 96 Kit (Zymo) and ddPCR was performed using the QX600 AutoDG Droplet Digital PCR System (Bio-Rad) to quantify the integration event at GS10. Each test sample was prepared using a 4x ddPCR™ multiplex mix (Bio-Rad) for probes; forward / reverse primers (900 nM); PrimeTime™ qPCR probes labeled with FAM, HEX, Cy5, or Cy5.5 (250 nM); HindIII-HF restriction enzyme (NEB); and 20–50 ng of DNA template. Droplets of the reaction mixture were generated using an automated droplet generator, and DNA amplification was performed in the generated droplets using a PTC Tempo DeepWell thermal cycler (Bio-Rad), followed by enzyme inactivation. The droplets were then quantified using a QX600 droplet reader (Bio-Rad). Data analysis was performed using QX Manager (Bio-Rad) to count positive and negative droplets for each probe and to calculate integration events relative to RPPH1, which serves as a genome copy number reference.
[0241] Significant CAR expression was observed in primary human T cells by flow cytometry. Figure 13A CAR integration at the GS10 site was demonstrated by ddPCR using the variant LSR. Figure 13B ).
[0242] Example 10: Integration of CAR into human primary T cells by cssDNA and LSR delivered in LNP
[0243] CAR integration was further evaluated in human primary T cells with delivery of cssDNA in the LNP and the variant LSR mRNA (SEQ ID NO: 2024). The construct cssDNA18 (SEQ ID NO: 4009) was prepared as in Example 1. The LSR variant construct was 3xMyc-NLS-Flag-LSR as mRNA.
[0244] LNPs were prepared using ionizable lipids, auxiliary lipids (DSPC (BP-25623)), cholesterol (BP-26125), PEG lipids (DMG-PEG 2000 (BP-25496)), and modified PEG lipids, and dissolved in ethanol at a ratio of 50:25:22:2.5:0.5. The lipid mixture was combined with an acidic aqueous buffer containing mRNA and / or cssDNA at a volume ratio of 3:1 (water:ethanol) using a microfluidic mixer (Ignite, Precision Nanosystems). The LNPs were conjugated with anti-CD3Fab fragments (containing SEQ ID NO: 2031 and 2032 for the heavy and light chain variable regions, respectively). The formulation was dialyzed in a dialysis cassette against 50 mM Tris (pH 7.5), 75 mM NaCl, and 10% sucrose for at least 18 hours. The nucleic acid concentration within the LNPs was determined using RiboGreen (R11491, ThermoFisher). Store the formulation at -80°C until further use.
[0245] Cryopreserved T cells were obtained from Stemcell Technologies. T cells were thawed and activated in CTS OpTmizer T cell expansion medium (Gibco) supplemented with 2% human AB serum (Fisher), 100 IU / mL IL-2, 10 ng / mL IL-7, 10 ng / mL IL-15 (Stemcell Technologies), and a 1:100 dilution of TransAct (Miltenyi). Cells were seeded at 100,000 cells / well in 96-well plates and incubated overnight. The next day, T cells were treated with 5 µg / mL of LNPs encapsulated with cssDNA or nanoparticles, and co-delivered with 1 µg / mL, 3 µg / mL, or 5 µg / mL LSR mRNA LNPs. All LNP treatments were co-delivered with 4 µg / mL ApoE. Controls included cssDNA-only LNPs, nanoparticle-only LNPs, and culture medium-only groups.
[0246] CAR-positive T cells were detected by flow cytometry on day 7, as shown in... Figure 14 As shown in the figure, and increases with larger LSR doses.
[0247] Example 11: CSSDNA integration in HEK293FT cells with oligonucleotides
[0248] cssDNA integration was tested by adding oligonucleotides of various lengths and by using locked nucleic acids (LNAs) at various positions on the oligonucleotides in HEK293FT cells transfected with Lipo3000. The construct cssDNA10 (SEQ ID NO: 4008) was prepared as described in Example 1. The LSR variant construct was 3xMyc-NLS-Flag-LSR as mRNA with the LSR variant (SEQ ID NO: 2024).
[0249] The addition of antisense oligomers led to enhanced integration of cssDNA, as measured by the percentage of integration at the GS10 site. Figure 15A -B). Locking nucleic acids further enhances integration ( Figure 15C -D). Although enhanced integration was observed by ddPCR, no difference in GFP transgene expression was observed compared to cssDNA in the absence of oligonucleotides.
[0250] Example 12: In vitro CAR-T generation using cssDNA encoding CAR in LNP
[0251] CAR-T cells were generated in vitro by incubating primary human T cells with CD3-targeting LNPs containing individual LSR mRNA, individual cssDNA encoding CD19 CAR, or co-encapsulated LSR mRNA and cssDNA encoding CD19 CAR (cssDNA19) (SEQ ID NO: 5000). The LSR variant construct was a 3xMyc-NLS-Flag-LSR containing the LSR variant (SEQ ID NO: 2024) mRNA. LNPs were prepared using anti-CD3 Fab fragments (containing SEQ ID NO: 2031 and 2032 for the heavy and light chain variable regions, respectively) as in Example 11. cssDNA was prepared as in Example 1.
[0252] CAR-T cells were prepared and analyzed as follows. Cryopreserved human T cells were obtained from Stemcell Technologies. The T cells were thawed and resuspended at 1,000,000 viable cells / mL in X-Vivo15 medium (Lonza) supplemented with 2% human AB serum (Fisher), 100 IU / mL IL-2, 10 ng / mL IL-7, and 10 ng / mL IL-15 (Stemcell Technologies). T cells were seeded at 100,000 cells / well in 96-well plates, in duplicate or triplicate, and treated with CD3-targeted LNP at the concentrations shown in each figure. Additional cytokines were administered to the T cells every 2–3 days. On day 6, CAR expression in T cells was analyzed by flow cytometry. Figure 16A And T cell integration was analyzed using ddPCR. Figure 16B ).
[0253] To analyze CAR expression by flow cytometry, T cells were stained with an antibody conjugated to a fluorophore targeting the anti-CD19 CAR and analyzed on a Thermo Fisher Attune NxT flow cytometer. Data were analyzed using FlowJo 10.10.0 software (TreeStar).
[0254] For integration analysis via ddPCR, cells were lysed using 100 μL of genomic lysis buffer from the Quick-DNA™ 96 kit (Zymo Research, D3012) according to the manufacturer's instructions, and ddPCR was performed using a QX600 AutoDG Droplet Digital PCR System (Bio-Rad) to quantify the integration event at the GS10 site. 100 ng of DNA was used per reaction. Each test sample was prepared using 2x ddPCR™ Supermix (dUTP-free) (Bio-Rad) for probes, forward / reverse primers (900 nM), FAM or HEX-labeled PrimeTime™ qPCR probes (250 nM), HindIII-HF restriction enzyme (NEB), and 20–50 ng of DNA template. Droplets of the reaction mixture were generated using an automated droplet generator, and DNA amplification was performed in the generated droplets using a PTC TempoDeepWell thermal cycler (Bio-Rad), followed by enzyme inactivation. The droplets were then quantified using a QX600 droplet reader (Bio-Rad). Data analysis was performed using QX Manager (Bio-Rad) to count positive and negative droplets for each probe and to calculate integration events relative to RPPH1, which serves as a genome copy number reference.
[0255] Example 13: In vivo assay of LNP targeting LNP in NSG mice using CD3 co-encapsulated LSR mRNA and CAR-encoding cssDNA. Internal CAR-T generation
[0256] In vivo CAR-T cell production was demonstrated by IV delivery of a co-encapsulated mRNA encoding a variant LSR and a cssDNA donor template encoding a CD19 CAR transgene. The construct cssDNA19 (SEQ ID NO: 5000) was prepared as described above. The LSR variant construct was 3xMyc-NLS-Flag-LSR containing the mRNA of the LSR variant (SEQ ID NO: 2024).
[0257] As described in Example 11 above, CD3-targeting LNPs were prepared using primary T cells and their ability to mediate CAR expression and integration in vitro was verified.
[0258] NSG mice were administered CD3-LNP via tail vein transplantation of human CD34+ stem cells, and the dosage for each group is listed in Table 3. Mice in group 3 received LNPs co-encapsulated with cssDNA and mRNA at a 1:1 ratio.
[0259] Table 3: LNP levels and in vivo study doses in the treatment group
[0260]
[0261] Animals were euthanized on day 8 post-administration. Several tissues, including whole blood, spleen, bone marrow, and mesenteric lymph nodes, were collected and dissected. Whole blood was stained and measured by flow cytometry as described in Example 12. Other tissues, including splenic leukocytes, bone marrow-derived leukocytes, and lymph node-derived leukocytes, were prepared for staining by transferring 200 µL of each dissected sample into each well of a 96-well U-shaped plate. For bone marrow-derived leukocytes, the sample was first passed through a sieve filter to remove particulate debris before being added to the wells. The plate was centrifuged at 500 x g for 5 min at ambient temperature to precipitate the cells. The supernatant was discarded in a biohazard container. All cell pellets were resuspended in a 50 µL mixture of human and mouse Fc receptor blockers (human TruStain FcX, BioLegend, 422302; and TruStain FcX anti-mouse CD16 / 32, BioLegend, 101320) diluted 1:20 in buffer. Incubate the plate at 4°C in the dark for 20 minutes. Add 25 µL of antibody mixture to each well without washing. To measure CAR expression on the surface of T cells, add an antibody specific for CD19 CAR at a 1:50 dilution to the antibody mixture before adding it to the plate. Incubate the tissue-derived cells at 4°C in the dark for 20 minutes. After incubation, add 150 µL of buffer to each well and centrifuge the plate as previously described. Discard the supernatant in a biohazardous container and repeat the washing step a second time using 200 µL of buffer. After discarding the supernatant from the second wash, resuspend all tissue-derived cells in 200 µL of buffer and acquire results on a flow cytometer as described. In each sample type, CD45 expression is first measured on individual live cells. + CD3 in the population + The event is gated, and then forward scattering is plotted against the CAR+ signal to measure the frequency of CAR-T cells.
[0262] Terminal tissue analysis by flow cytometry on day 8 post-treatment showed a significant reduction in B cells. Figure 17A And T cells showed no significant changes. Figure 17B ).
[0263] Direct evidence of in vivo CAR-T cell production was found in T cells of the spleen of a mouse treated with LNPs co-encapsulated with LSR + cssDNA. In mice treated with LNPs co-encapsulated with LSR + cssDNA... Figure 17C ) and mice treated with LNP containing only cssDNA ( Figure 17D CAR expression was measured in spleen T cells by flow cytometry.
[0264] As the average of all mice in a group ( Figure 17E ) and for each individual mouse that had been given LNPs co-encapsulated with LSR + cssDNA ( Figure 17F LSR-mediated CAR integration was demonstrated by ddPCR in terminal tissues. To prepare genomic DNA from the samples, 100 µl of whole blood was treated with red blood cell lysis buffer at room temperature for 10 min, centrifuged at 1000 rpm for 5 min, the supernatant was discarded, and the cell pellet was used for genomic DNA extraction. Other samples, including spleen, bone marrow, and mesenteric lymph nodes, were treated into single-cell suspensions, and 1e6 cells were transferred to each well of a 96-well plate. Cells were lysed with 100 µl of genomic lysis buffer from the Quick-DNA™ 96 Kit (Zymo Research, D3012) according to the manufacturer's instructions. 100 ng of genomic DNA was used for each reaction, and ddPCR was performed as described above.
[0265] Example 14: In vivo antitumor activity of integrated CD19 CAR-T cells
[0266] The antitumor activity of CD19 CAR-T cells co-encapsulated with mRNA encoding the variant LSR and with cssDNA templates encoding the CD19 CAR transgene targeting LNPs was evaluated in a tumor-regressed mouse model (NSG-MHCI / II-DKO mice). Two genome-targeting LSR variants, “LSR-A” (SEQ ID NO: 2024) and “LSR-B” (SEQ ID NO: 2029), were tested using the same AttD (SEQ ID NO: 2025) and integrated at the GS10 site. PBMCs were purchased from iXCells Biotechnologies USA, Inc. CD3-targeting LNPs were prepared using CD3 Fab as described above.
[0267] On day -3, mice were intravenously injected with 2.5 x 10e⁵ tumor cells (Nalm 6-luciferase). On day 0, mice were intravenously injected with 20e⁶ PBMCs, followed by intravenous administration of LNP. Mice were administered 1 mg / kg LNP per mouse in the following groups: 1) CD3-targeting LNP co-encapsulated with LSR mRNA and cssDNA encoding CD19-CAR; and 2) CD3-targeting LNP co-encapsulated with LSR mRNA and mScarlet mRNA (“LSR mRNA only”). A control group for addotype expression was given 0.5 mg / kg (“DNA only”) of CD3-targeting LNP encapsulated with nanoparticle DNA encoding only CD19-CAR. Other controls included a tumor-based baseline control group, in which T-cell controls received IV injections of tumor cells and PBMCs but not LNP, and another tumor-based baseline control group for IVIS imaging that did not receive IV injections of any tumor cells, PBMCs, or LNP.
[0268] Tumor burden was assessed by IVIS imaging on days -1, 4, 7, 10, 14, 19, 26, and 33. Mice were injected intraperitoneally (IP) with 15 mg / mL D-luciferase solution in D-PBS (150 mg / kg) and maintained on 2.5% isoflurane via a nasal cone connected to an internal anesthesia manifold. Mice were placed on a heated (37°C) rack in the imaging chamber of the AMI HTX Spectral Instruments system for ventral image acquisition. Bioluminescence signals were quantified using Aura In VivoImaging software (Spectral Instruments) according to the manufacturer's instructions. Total throughput (p / s) was used to indicate the intensity of the luciferase signal.
[0269] Tumor reduction was observed in LNPs co-encapsulated with LSR mRNA and CD19-CAR transgenes. Figure 18A CD3-targeted LNP was well tolerated, with moderate weight loss in all groups, followed by recovery.
[0270] Relevant assessments showed CD19-CAR integration and the production of CAR-T cells in the blood. Integration was assessed by ddPCR as described above, and the result was measured as the sum of the first eight integration sites. Data from individual mice at days 4 and 26 are shown. Figure 18B In mice receiving LNPs co-encapsulated with LSR mRNA and cssDNA encoding the CD19-CAR transgene, CAR+ T cells (CD3+ T cells) were detected by flow cytometry as described above at specified time points following LNP administration. Figure 18CCAR+ T cells were not detected in the augmented expression control. The percentage of CD20+ cells in the CD45+ cell population was measured by flow cytometry, and B cell depletion from PBMCs was assessed 10 days after LNP administration.
[0271] The above results demonstrate functional CAR integration and tumor reduction in CD3-targeting LNP-containing NSG mice with co-encapsulated LSR mRNA and cssDNA encoding the CD19-CAR transgene.
[0272] Example 15: cssDNA:RNA ratio of LNP preparation in primary T cells
[0273] The cssDNA to mRNA ratio was evaluated by testing five LNP formulations: LNP-1 (cssDNA:mRNA ratio 1:1); LNP-2 (cssDNA:mRNA ratio 2:1); LNP-3 (cssDNA:mRNA ratio 1:2); LNP-4 (cssDNA:mRNA ratio 3:1); and LNP-5 (cssDNA:mRNA ratio 1:3). LNP-6 was a control without mRNA.
[0274] Five lipids (ionizable lipids, accessory lipids (DSPC (BP-25623)), cholesterol (BP-26125), PEG lipids (DMG-PEG 2000 (BP-25496))) and modified PEG lipids) were dissolved in ethanol at a ratio of 50:25:22:2.5:0.5. The lipid mixture was combined with an acidic aqueous buffer containing mRNA and / or cssDNA at a volume ratio of 3:1 (water:ethanol) using a microfluidic mixer (Ignite, Precision Nanosystems). The LNPs were then incubated and labeled with ligands targeting T cells. The formulation was dialyzed in a dialysis cassette against 50 mM Tris (pH 7.5), 75 mM NaCl, and 10% sucrose for at least 18 hours. The nucleic acid concentration within the LNPs was determined using RiboGreen (R11491, ThermoFisher). The formulation was stored at -80°C until further use.
[0275] Primary T cells (Stemcell Tech, 70024.1) were thawed and incubated overnight. The next day, 100k cells were placed in flat-bottomed 96-well plates. LNP was applied directly to each well. Cells were incubated for four days, and then the percentage of CAR+ cells was evaluated by flow cytometry. Figure 20A ), and the integration percentage at the GS10 integration site was evaluated by ddPCR (). Figure 20B ).
[0276] Example 16: The CSSDNA generated by enzymatic transformation is active for LSR-mediated integration.
[0277] Evaluation of CSSDNA production using enzymatic transformation processes without phage systems ( Figure 21A The starting material was a double-stranded plasmid containing all seven BbvI sites on the same strand. Figure 21B The enzyme and 10x reaction buffer (CutSmart) were purchased from New England Biolabs. The reaction was established using 40 ng / µl plasmid DNA, 0.04 μL / µl BbvCI, 0.2 μL / µl Nt.BbvCI, 1 μL / µl T7 exonuclease, and 1x CutSmart buffer in 50 µl, and incubated at 37°C for approximately 16 hours. The reaction was analyzed by gel electrophoresis on a 1% agarose TAE gel cast with SybrGold staining. Figure 21C ).
[0278] CSDNA was purified by anion exchange chromatography. The reaction mixture was diluted 1:33 in equilibration buffer (100 mM Tris HCl pH 8.0, 300 mM guanidine HCl, 100 mM NaCl) and loaded onto a DEAECIMmultus Monolithic column with 6 µm wells. The column was washed with equilibration buffer, and then the CSDNA was collected by elution buffer (100 mM Tris HCl pH 8.0, 300 mM guanidine HCl, 1,000 mM NaCl). All procedures were performed on an AktaAvant FPLC instrument. A chromatogram showing the purified CSDNA is displayed. Figure 21D middle.
[0279] Purified cssDNA or parental dsDNA plasmids were electroporated together with the LSR variant (SEQ ID NO: 2030) (a genome-targeting LSR) as described above into primary human T cells (both donors tested). AttD is SEQ ID NO: 2025. Integration of the DNA payload (cssDNA or plasmid dsDNA) at the GS10 integration site was measured by ddPCR. Figure 21E ).
[0280]
Claims
1. A genome editing system, the genome editing system comprising: a. mRNA encoding large serine recombinase (LSR); as well as b. Circular single-stranded DNA (cssDNA) containing a donor attachment site (AttD) and the sequence of interest; The genome editing system described therein is capable of integrating the sequence of interest into the cell genome.
2. The genome editing system of claim 1, wherein the genome editing system further comprises a lipid-based formulation comprising (a) and (b).
3. The genome editing system of claim 1, wherein the genome editing system further comprises a first lipid-based formulation comprising (a) and a second lipid-based formulation comprising (b).
4. The genome editing system of claim 2 or 3, wherein the lipid-based formulation is LNP.
5. The genome editing system according to any one of claims 1 to 4, wherein the ratio of b) to a) in the genome editing system is 3:1 to 1:3, or wherein the ratio of b) to a) in the genome editing system is 2:1 to 1:
2.
6. The genome editing system according to any one of claims 1 to 5, wherein the ratio of b) to a) in the genome editing system is 1:
1.
7. The genome editing system according to any one of claims 1 to 6, wherein the endotoxin level of (b) is less than 0.1 EU / µg, less than 0.05 EU / µg, 0.01 EU / µg, or 0.005 EU / µg.
8. The genome editing system of any one of claims 1 to 7, wherein the sequence of interest comprises a gene or a portion thereof.
9. The genome editing system of any one of claims 1 to 8, wherein the sequence of interest comprises a therapeutic protein.
10. The genome editing system of any one of claims 1 to 9, wherein the sequence of interest comprises a CAR.
11. The genome editing system of any one of claims 1 to 10, wherein the LSR is a genome-targeting LSR.
12. The genome editing system of any one of claims 1 to 11, wherein the LSR is not a landing pad LSR.
13. The genome editing system of any one of claims 1 to 12, wherein the genome editing system comprises a lipid-based formulation, including a lipid-based formulation comprising cationic lipids, auxiliary lipids, cholesterol and PEG lipids.
14. The genome editing system of claim 13, wherein the lipid-based formulation further comprises a peptide.
15. The genome editing system of any one of claims 2 to 14, wherein the lipid-based formulation comprises LNPs with a size of 50-100 nm.
16. The genome editing system of any one of claims 1 to 15, the genome editing system comprising a) a first lipid-based formulation and b) a second lipid-based formulation, wherein the first lipid-based formulation and the second lipid-based formulation are substantially identical in composition and size.
17. The genome editing system of any one of claims 1 to 16, the genome editing system comprising a) a first lipid-based formulation and b) a second lipid-based formulation, wherein the first lipid-based formulation and the second lipid-based formulation are different in composition and size.
18. The genome editing system of any one of claims 1 to 17, wherein the AttD site comprises at least 26, 34, 36, 39, 48, or 52 nucleotides, wherein the nucleotides comprise a dinucleotide core and an even number of nucleotides directly adjacent to either side of the dinucleotide core.
19. The genome editing system of any one of claims 1 to 18, wherein the AttD site comprises the AttP site.
20. The genome editing system of any one of claims 1 to 19, wherein the cell genome is a human genome.
21. The genome editing system of any one of claims 1 to 20, wherein the cellular genome does not contain an attachment site for installation.
22. A method for integrating a sequence of interest into a cell genome, the method comprising contacting a cell with a genome editing system as described in any one of claims 1 to 21, such that the sequence of interest is integrated into the cell genome.
23. A method for producing engineered cells, the method comprising contacting the cells with a genome editing system as described in any one of claims 1 to 21.
24. A method for introducing a sequence of interest into a cell, the method comprising contacting the cell with a genome editing system as described in any one of claims 1 to 21.
25. The method of any one of claims 22 to 24, wherein the cell is a mammalian cell, and optionally wherein the cell is a human cell.
26. The method of claim 25, wherein the cell is a T cell, a natural killer cell (NK cell), a non-human embryonic stem cell, an induced pluripotent stem cell (iPSC), a hematopoietic stem cell (HSC), a hepatocyte, a myocyte, a monocyte, a B cell, a neuron, an astrocyte, or a microglia.
27. The method of claim 26, wherein the cell is a T cell.
28. The method of any one of claims 22 to 27, wherein the contact of the cells is in vivo.
29. The method of any one of claims 22 to 27, wherein the contact of the cell is ex vivo.
30. The method of any one of claims 22 to 29, wherein Cas or guide RNA is not used in the contact of the cells.
31. The method of any one of claims 22 to 30, wherein the method does not include modifying the cell to insert the attachment site of the sequence of interest into the cell genome.
32. An engineered cell comprising the genome editing system as claimed in any one of claims 1 to 21.
33. The engineered cell of claim 32, wherein the cell is a human cell.
34. The engineered cell of claim 32 or 33, wherein the cell is a T cell, a natural killer cell (NK cell), a non-human embryonic stem cell, an induced pluripotent stem cell (iPSC), a hematopoietic stem cell (HSC), a hepatocyte, a myocyte, a monocyte, a B cell, a neuron, an astrocyte, or a microglia.
35. A method for treating a disease in a subject, the method comprising administering to the subject a genome editing system as described in any one of claims 1 to 21 or engineered cells as described in any one of claims 32 to 34.
Citation Information
Patent Citations
Serine recombinases
WO2023081762A2
